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ABSTRACT
Hypertension is a serious condition with high morbidity and mortality rates, as well as a major
predisposing factor for multiple cardiovascular and renal diseases. Angiotensin II (Ang II) of the
renin-angiotensin system (RAS) plays a pivotal role in propagating the hypertensive response.
Moreover, hypertension is considered a chronic low-grade inflammatory condition that
intimately involves the actions of proinflammatory cytokines (PICs) such as tumor necrosis
factor-alpha (TNF). Recent evidence highlights the role that inflammation, specifically TNF,
plays in hypertension and in regulating the RAS, but the understanding as to how inflammation
is regulated following Ang II or TNF activation, as well as the resultant consequences, is
currently unclear. Based upon the literature and work from our laboratory, we hypothesize that
inflammatory regulation in local tissues alters the systemic hypertensive response, possibly
through an inflammatory-driven reactive oxygen species (ROS) mechanism. Therefore, we
examined the role of inflammatory mediators in the heart and brain in regulating the
hypertensive response through the modulation of ROS, the transcription factor Nuclear FactorkappaB (NFκB) and the dysregulation of components of the RAS. To examine this interaction,
we conducted a series of in vivo experiments designed to better understand these mechanisms.
First, we evaluated the effects of TNF infusion on blood pressure response and RAS component
expression in the heart. We further explored these inflammatory mechanisms in spontaneously
hypertensive rats through the actions of histone deacetylases in maintaining the hypertensive
state through inflammatory modulation. Next, we examined the interaction of TNF in the brain in
regulating the RAS in the Ang II-induced hypertensive drive. Finally, we examined how NFκB
in the hypothalamic paraventricular nucleus contributed to the dysregulation of the RAS and
adverse pressure responses in Ang II-induced hypertension. Combined, these studies demonstrate

xiii

a functional and signaling dependence between PICs and the RAS in hypertension, potentially
through a ROS-mediated mechanism. These findings provide insight into the important signaling
pathways involved in hypertension, as well as outline potential future therapeutic targets for the
continued fight against this debilitating disease.

xiv

CHAPTER 1
INTRODUCTION AND REVIEW OF LITERATURE

1

HYPERTENSION
The World Health Organization (WHO) lists hypertension as one of the world’s great
public health problems and the leading cause of death worldwide (2002). Within the United
States, the Centers for Disease Control (CDC) and the American Heart Association (AHA)
conclude that more than 74 million American adults, or 1 in 3 ages 20 and over, have high blood
pressure (Lloyd-Jones, Adams et al. 2010). Less than 78% of these people know that they suffer
from hypertension, and of those that are aware, less than 68% are currently being treated.
Hypertension is not only a serious condition with its own high morbidity and mortality rates, it is
also a major risk factor for multiple cardiovascular diseases (CVDs), including myocardial
infarction, stroke, heart failure, atrial fibrillation, aortic dissection and peripheral arterial disease.
Moreover, with the rise in extraneous causes for increased blood pressure, including obesity, salt
intake, poor lifestyle choices and a growing population of aging individuals, the incidence of
hypertension is rising (Lloyd-Jones, Adams et al. 2010). While physicians do not know the cause
for more than 90-95% of their hypertensive patients, the condition is easily detectable. However,
and even more disturbing, is that of these individuals, more than half do not have their
hypertension under control. In 2006 alone, greater than 56,000 people died in the United States
from this debilitating condition.
Hypertension is classified as a systolic/diastolic blood pressure of 140/90 mmHg or
higher. However, with epidemiological data suggesting significant increases in CVDs developing
at lower pressures, the current definition remains contentious. As a result, physicians are
becoming increasingly wary of pre-hypertensive conditions and initiating therapeutics more
proactively. Hypertension can be further broken down into primary (essential) or secondary
(identifiable) hypertension. In primary hypertension, a single reversible cause for the elevated
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blood pressure cannot be identified, roughly accounting for the 90-95% of hypertensive cases
observed. For the remaining 5-10% of clinical cases, a more distinct cause can be detected,
falling under the moniker secondary hypertensive.
Current therapeutics for primary hypertension are multiple and varied, exploiting the
many endogenous controlling mechanisms of normal pressure response as well as the
pathophysiological hypertensive contributors. Briefly, these therapies can include lifestyle
modifications and/or a bevy of pharmacological therapeutics. Lifestyle modifications can include
weight reduction, sodium reduction, diet modification, increased physical activity and
moderation of alcohol and tobacco consumption, amongst others. Common pharmacological
interventions can include any number of drugs alone or in combination, including, but not
limited to, diuretics, β-blockers, α-blockers, Ca2+ channel blockers, angiotensin converting
enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) (Izzo, Sica et al. 2008).
However, many current therapeutics fail to have a beneficial effect on over 50% of treated
individuals, prompting the need for novel therapeutic approaches and a greater understanding of
the mechanistic pathways involved in the pathogenesis and maintenance of hypertension.
THE FUNCTION OF THE RENIN-ANGIOTENSIN SYSTEM IN HYPERTENSION
The Renin-Angiotensin System in Normal Physiology. There are many controlling factors for
normal blood pressure regulation, including local autoregulation, baroreceptor signaling and the
renin-angiotensin-aldosterone system (RAAS, herein referred to as RAS for renin-angiotensin
system) (Guyton and Hall 2006). In its classically understood pathway, following a decrease in
blood pressure, the RAS becomes activated. A reduced blood pressure decreases glomerular
filtration rate, therefore increasing the time that the filtrate can undergo reabsorption, leading to
an increased reabsorption of sodium and chloride ions from the proximal tubules. The increased
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chloride concentration is detected by the macula densa of the kidneys and causes the release of
renin from the juxtaglomerular cells of the afferent artery. Circulating renin cleaves circulating
angiotensinogen (produced and released by the liver) into the decapeptide angiotensin I (Ang I),
which is subsequently converted by ACE (abundantly synthesized and located within the
vasculature of the lungs) into the biologically active octapeptide angiotensin II (Ang II). Ang II
is the primary effector peptide of the RAS, eliciting its actions through either Ang II type-1 or
type-2 receptors (AT1R and AT2R, respectively) (Allen, Zhuo et al. 2000; Lavoie and Sigmund
2003). The AT1R is the main receptor through which Ang II acts, inducing vasoconstriction,
aldosterone secretion, increased sympathetic activation and sodium retention, amongst its many
other actions, all intended to raise blood pressure to its homeostatic levels (Allen, Zhuo et al.
2000). Once normalized, these same factors negatively signal back upon themselves to shut off
these arterial pressure raising functions. The AT2R, the less common of the two receptors, is
thought to be cardioprotective and display actions opposing those of the AT1R, but this concept
remains poorly understood. Though the following depicts the classical RAS (also see Figure 1.1),
recent research has shown that a majority of the tissues within the body have their own local
RAS, including the heart, vasculature and brain, and that these tissue systems are capable of
producing all the associated components of the classical RAS (Lavoie and Sigmund 2003).
Further complicating the original understanding of the RAS was the identification of a
separate RAS axis that exhibited cardioprotective properties and seemed to be a counterbalance
to the actions of Ang II. Following its initial discovery in 2000, ACE2 was shown to cleave Ang
I into Ang (1-9), which is subsequently converted to Ang (1-7) by ACE (Donoghue, Hsieh et al.
2000; Tipnis, Hooper et al. 2000; Xu, Sriramula et al. 2011). Ang II can also be converted by
ACE2 to Ang (1-7) (Vickers, Hales et al. 2002). By acting through the Mas receptor (MasR),
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Ang (1-7) has actions that oppose those of Ang II, including vasodilatation and anti-hypertrophic
properties (Santos, Simoes e Silva et al. 2003). Additional pathways by which the components of
the RAS can act are increasingly coming under investigation. The AT4R subtype, the roles of
Ang III and Ang IV, the chymase activation pathway and a non-AT1/non-AT2R are a few of the
various novel mechanisms currently being studied (Xu, Sriramula et al. 2011). Regardless, these
diverse systems highlight the major difference from our traditional understanding of the RAS to
this multifaceted system that is only recently becoming more elucidated.

Figure 1.1. The components of the renin-angiotensin system. The balance between the
vasoconstrictor/pro-hypertensive and vasodilator/anti-hypertensive axes are critical to the
maintenance of blood pressure control and the perpetuation of hypertension. Ang, Angiotensin;
ACE, Ang converting enzyme; NEP, Neutral endopeptidase; AT1 and AT2R, Ang II Type-1
and Type-2 receptor, respectively.
5

The RAS in Hypertension. Under typical blood pressure homeostasis, the RAS and its various
components function without producing a pathological condition. However, following any of the
many triggers that can induce the commencement of a hypertensive response, the RAS becomes
intimately involved in its pathogenesis. As such, understanding its function within the
hypertensive state is of constant concern. In hypertensive human patients and multiple
hypertensive animal models, Ang II is elevated, along with AT1R expression and increased
AT1R cell surface localization, thereby heightening tissue sensitivity to the already elevated Ang
II (Atlas 2007). These tissue responses to Ang II in hypertension are multiple. Initially, a
pathological increase in Ang II can lead to sustained elevation of blood pressure through multiple
avenues: direct sustained vasoconstriction; increased salt (Na+) and water retention through
direct actions on the kidney tubules, indirectly via aldosterone stimulation and secretion, and/or
indirectly via posterior pituitary stimulation and secretion of anti-diuretic hormone (ADH or
vasopressin), increased chronic sympathetic activity, etc (Corvol and Jeunemaitre 1997; RuizOrtega, Lorenzo et al. 2001). These factors, combined with additional specific responses of
individually activated tissues, exacerbate the hypertensive response and lead to a general
deterioration of cardiovascular function and response capabilities.
Over time, sustained elevation of Ang II can also lead to cardiovascular hypertrophy and
remodeling, further deteriorating the hypertensive condition (Sasamura, Nakazato et al. 1997;
Allen, Zhuo et al. 2000; Paradis, Dali-Youcef et al. 2000; Lim, Lutucuta et al. 2001; RuizOrtega, Lorenzo et al. 2001). Within the heart, Ang II signals cell proliferation and
differentiation and cardiomyocyte hypertrophy (Lim, Lutucuta et al. 2001). Additional signaling
cascades result in cardiomyocyte contractile dysfunction, interstitial fibrosis, conductance and
rhythm defects and a decompensation of cardiac function, which can be reversed by Ang II
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receptor blockade (Paradis, Dali-Youcef et al. 2000). This increased remodeling, hypertrophy
and heart contractile deficiencies leads to increased peripheral resistance, causes vessel damage,
dysfunction of normal vascular mechanisms, and can lead to plaque buildup and atherosclerosis,
a major factor for the high morbidity and mortality associated with hypertension (Atlas 2007).
Simultaneously, with this increase in the activity of the ACE/Ang II/ AT1R axis comes the
decrease in the protective ACE2/ Ang (1-7)/MasR axis, further reducing the possible
cardioprotective and anti-hypertensive effects that this newly recognized arm of the RAS may
produce (Xu, Sriramula et al. 2011). Combined, these functions of Ang II are major reasons for
the need to control this peptide in hypertension and the rationale behind the use of ACE
inhibitors and ARBs in hypertensive therapy (Atlas 2007).

Activities of the ReninAngiotensin System
HYPERTENSION

Hypertrophy
Remodeling
Heart Failure

Vasoconstriction
Hypertrophy
Remodeling
Atherosclerosis

Sympatho-excitation Renal Failure
Stroke

Hypertensive
retinopathy

Figure 1.2. Effect of the RAS on organ damage in hypertension. Increased RAS activity
is critical in the development and maintenance of hypertension and may lead to end organ
damage.
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Taken together, the RAS in hypertension is a complicated association of beneficial and
deleterious components whose functional interplay is only beginning to come of light.
Understanding their functions and the mechanistic pathways by which the RAS is activated and
sustained in various tissues in hypertension is instrumental for the advancement of novel
therapeutic options, including promoting ACE2 expression and Mas receptor agonists. However,
these concepts are intensified in complexity when considering their effect on and their regulation
by inflammatory mediators in hypertension.
INFLAMMATION, NUCLEAR FACTOR-κB IN HYPERTENSION
Inflammation is associated with many CVDs, and recent evidence suggests that
hypertension is a chronic low-grade inflammatory condition (Ferrario and Strawn 2006;
Sriramula, Haque et al. 2008; Kang, Ma et al. 2009; Cardinale, Sriramula et al. 2010). Proinflammatory cytokines (PICs) such as Tumor Necrosis Factor-alpha (TNF), interleukin (IL)-1β
and IL-6, have emerged as major contributing factors in the pathogenesis of hypertension and
other CVDs (Mann 2002; Ruiz-Ortega, Ruperez et al. 2002; Sriramula, Haque et al. 2008; Kang,
Ma et al. 2009). The RAS, especially the effector peptide Ang II, not only modulates the
hypertensive response through the above mentioned mechanisms, but plays a key role in
inducing the inflammatory response associated with hypertension (Kalra, Sivasubramanian et al.
2002). Moreover, this inflammatory response appears to upregulate both local and systemic prohypertensive components of the RAS while silencing those of the anti-hypertensive axis. The
Ang II-mediated inflammatory response can occur through several mechanisms, including
activation of monocytes and macrophages, as well as induce the production of adhesion
molecules, chemokines, cytokines and ROS activators (Arenas, Xu et al. 2004; Shi, Diez-Freire
et al. 2010). While still not fully known, these pathways are becoming more important to
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understand, as it is increasingly clear that inflammation plays a major role in the
pathophysiological changes observed in the cardiovascular system during sustained Ang IIinduced AT1R activation.
One of the primary cytokines activated by Ang II is TNF. This pleiotrophic peptide exists
initially as a membrane bound pre-protein, which once cleaved by metalloproteinases into its
soluble form, can elicit its responses through one of two similarly acting TNF receptors, TNFR1
(low affinity) or TNFR2 (high affinity) (Gearing, Beckett et al. 1994; Feldman, Combes et al.
2000; Mann 2002). Once receptor bound, TNF plays an important role in multiple
pathophysiological processes, as in hypertension, such as inflammation, cell survival, growth,
differentiation and apoptosis (MacEwan 2002). There is much data to support the cross-talk
between the RAS and PICs, such as TNF, a conversation often shown to involve the mediation
effects of the transcription factor Nuclear Factor-kappaB (NFκB) (Mehta and Griendling 2007;
Kang, Ma et al. 2009).
NFκB is a key transcription factor regulating many inflammatory and immune responses
(Bubici, Papa et al. 2006). This protein signaling cascade is highly complex, with multiple
members within the “Rel” and “NFκB” related family of proteins, including RelA (p65), RelB,
c-Rel, p50, p52, and additional, less widely distributes peptides, all capable of forming homoand heterodimers in vivo (with the exception of RelB which can only form a homodimer)
(Gilmore 2006). These subunits share a Rel-homology domain capable of binding various κB
binding sites on target genes and thereby inducing transcription. NFκB is typically sequestered
within the cytoplasm of cells and bound to one of several Inhibitory-κB (IκB) proteins such as
IκBα, IκBβ or IκBγ, amongst others. Following a signal from any number of possible receptors
(within hypertension: via AT1R, TNFRs and reactive oxygen species (ROS) signaling, etc.), IκB
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becomes phosphorylated (typically in hypertension: IκBα), leading to its subsequent ubiquination
and degradation. Once freed from IκB, NFκB (often the p50/RelA (p65) heterodimer is observed
in hypertension) then translocates itself into the nucleus and binds to its target genes, including
additional NFκB and IκB subunits (for negative feedback regulation/transcriptional repression)
(Gilmore 2006).
Recent evidence suggests the involvement of NFκB in the pathogenesis of cardiac
remodeling and in the failing heart (Kang, Ma et al. 2008; Kang, Ma et al. 2009; Cardinale,
Sriramula et al. 2010). Ang II has also been shown to activate NFκB and induce TNF in
cardiomyocytes (Cowling, Gurantz et al. 2002). For the hypertension-associated inflammatory
response, the p50/p65 dimer promotes gene expression increases for many proteins, including
TNF, inducible nitric oxide synthases (iNOSs), and inflammatory adhesion molecules
(Sriramula, Haque et al. 2008; Kang, Ma et al. 2009; Cardinale, Sriramula et al. 2010).
Activation of NFκB via Ang II not only induces increases in PIC expression, but also leads to
increases in ROS production and pro-hypertensive RAS component expression such as AT1R
and ACE, and has also been shown to decrease components of the ACE2/Ang (1-7)/Mas axis.
Therefore, understanding NFκB regulation and function within the hypertensive state in inducing
the deleterious interactions of the RAS, PICs and ROS is of great interest. Furthermore, in
clarifying these concepts, it provides the opportunity to develop novel therapeutic options for
controlling the damaging results of hypertension.
REACTIVE OXYGEN SPECIES IN HYPERTENSION
A growing body of evidence indicates that production of ROS and activation of
oxidation-reduction dependent signaling cascades leads to oxidative stress and is centrally and
critically involved cardiovascular events (Griendling, Sorescu et al. 2000; Touyz 2000; Harrison
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and Gongora 2009). ROS and oxidative stress play an important role in diabetes mellitus,
atherosclerosis, hyperlipidemia, heart failure, ischemic heart disease and hypertension. Oxidative
stress is defined as the imbalanced redox state where pro-oxidants overwhelm intrinsic antioxidant systems, resulting in an increased production of ROS. During normal physiological
conditions, ROS are produced in a controlled manner at low concentrations and function as
signaling molecules or normal by-products of cellular reactions and cellular respiration.
Conversely, under pathological conditions, increased ROS production contributes to cell
dysfunction, cell growth, monocyte invasion, lipid peroxidation, inflammation, and increased
deposition of extracellular matrix proteins, which are all important factors in vascular, renal and
cardiac damage during the pathogenesis of hypertension (Sawyer, Siwik et al. 2002; Murdoch,
Zhang et al. 2006; Papaharalambus and Griendling 2007).
In mammalian cells, aerobic respiration allows the reduction of molecular oxygen to
water. During this process, ROS are generated, including molecular free radical, protein and lipid
species. These species are short-lived, and after completing their roles in routine cellular
function/maintenance, they are scavenged by a series of antioxidant enzymes (Chabrashvili, Tojo
et al. 2002; Majid and Kopkan 2007; Paravicini and Touyz 2008); these highly reactive species
however, at elevated and/or uncontrolled concentrations, can interact with and cause damage to
proteins, lipids and DNA (Droge 2002; Vaziri 2008). Normally, the in vivo anti-oxidant defense
is sufficient to metabolize these ROS. However, in conditions of persistent inflammation and
oxidative stress, such as hypertension, anti-oxidant molecules and enzymes can be depleted
and/or inactivated, thereby impairing the overall anti-oxidant defense system (Droge 2002).
Although excessive production of ROS is the most common cause of oxidative stress in
hypertension, oxidative stress can also be caused by the primary impairment of antioxidant
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systems (Wei and Lee 2002; Ahamed and Siddiqui 2007). Under physiological conditions, ROS
produced in the course of normal metabolism are fully reduced by an elaborate cellular and
extracellular anti-oxidant defense system. However, in certain pathological conditions like
hypertension, increased generation of ROS and/or depletion of anti-oxidant capacity leads to
enhanced ROS activity and oxidative stress (Yu 1994; Vaziri, Wang et al. 2000). In fact, several
recent studies have demonstrated significant impairment of anti-oxidant enzymes and increased
oxidative stress in various models of hypertension, including spontaneously hypertensive (SHR)
rats (Carneado, Alvarez de Sotomayor et al. 2002; Elks, Mariappan et al. 2009) and rats with
chronic kidney failure (Galle 2001), diabetes (Mariappan, Elks et al. 2010), and Dahl-salt
sensitive rats (Wang, Chen et al. 2006; Tian, Moore et al. 2007).
Excessive ROS production causes oxidative damage and is associated with hypertension
and other disease conditions (Piotrkowski, Fraga et al. 2007; Puddu, Puddu et al. 2007). Growing
evidence from animal and clinical studies suggests that inflammation-induced oxidative stress in
the heart and kidney could be a key factor in the development and persistence of hypertension
(Cachofeiro, Goicochea et al. ; Vanegas, Ferrebuz et al. 2005; Van Gaal, Mertens et al. 2006).
Hypertension itself is a multi-factorial disorder that results from the combined effects of
inflammation, ROS, reactive nitrogen species generation, and lipid metabolism. Recent work
suggests that cytokines can modulate major ROS molecules, such as superoxide (·O2–) and nitric
oxide (NO), and contribute to hypertensive response (Elks, Mariappan et al. 2008; Sriramula,
Haque et al. 2008) and end organ damage (Elks, Mariappan et al. 2008; Mariappan, Elks et al.
2009). Under conditions of excessive ROS production, NO is also depleted, which is often from
either a direct decrease in NO (inhibition/depletion of nitric oxide synthase [NOS – converts Larginine into NO]) or because of a decreased bioavailability of NO due to its rapid interaction
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with superoxide to form peroxynitrite (Wilcox 2002; Palm 2006; PechÃ¡novÃ¡, Zicha et al.
2006). At high concentrations, peroxynitrite is also highly toxic to tissues and could be an
important signaling molecule and contributor to end organ damage in hypertension.
NO also has many known roles both peripherally and centrally in regulating blood
pressure responses. It acts as a vasodilator and neurotransmitter, and it is generally accepted that
the level of NO in the brain is inversely proportional to sympathetic outflow (i.e. decreased NO
is sympathoexcitatory) (Zucker and Liu 2000; Ramchandra, Barrett et al. 2005). While Ang II,
NO, and sympathetic regulation are known to interact, the mechanism is somewhat unclear
(Zucker and Liu 2000; Ramchandra, Barrett et al. 2005). Multiple experiments have shown that
Ang II infusion both in the periphery and via intracerebroventricular (ICV) cannulation
downregulates neuronal NOS (nNOS) in multiple cardio-regulatory regions in the brain,
including the paraventricular nucleus (PVN), coinciding with increased sympathetic outflow, and
that by scavenging ROS, these changes are reversed (Campese, Shaohua et al. 2005; Tai, Wang
et al. 2005). Additionally, in the presence of superoxide, NO is oxidized into peroxynitrite,
which further decreases the bioavailability of NO produced by an already diminishing presence
of nNOS (Zanzinger 2002). NOS overexpression studies also decreased the hypertensive state in
Ang II (Tai, Wang et al. 2005) and SHRSP (Kishi, Hirooka et al. 2003) animal models,
highlighting the role that NO plays in sympathetic regulation and blood pressure response.
Adding complexity to this system is inducible/inflammatory NOS (iNOS). Activated by Ang II
and NFkB (possibly through a redox sensitive mechanism), iNOS overexpression in the rostral
ventrolateral medulla (RVLM) causes an increase in sympathetic outflow and mean arterial
blood pressure (Kimura, Hirooka et al. 2005). The rationale for this phenomenon lies in the overefficiency displayed by iNOS compared to the other homologues. By rapidly converting all
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available L-arginine to NO, iNOS then begins to produce superoxide and further exasperate the
already fragile oxidant state. Thus, this evidence indicates that the increase in
sympathoexcitation and continuation of the hypertensive state is, in part, the result of a decreased
NO bioavailability in the brain, ultimately due to an increase in oxidative stress.
Although there is evidence that inflammation plays a key role in the pathophysiology of
hypertension, it is not clear whether inflammation induces oxidative stress to lead to
hypertension or that hypertension induces inflammation and oxidative stress. Regardless the
order, or if a combination of both, recent evidence shows that inflammation-induced oxidative
stress in hypertension can ultimately lead to heart and kidney failure, as well as an adverse
response in the brain and further contributing to the hypertensive response. The imbalance of
redox homeostasis is integral to the progression of the hypertensive state.
Sources of ROS. ROS are produced by numerous enzymes in many cell types, including
endothelial, vascular smooth muscle, adventitial, neuronal, microglial and various renal cells.
The major ROS produced are the superoxide anion (·O2–), hydroxyl moiety (·OH), hypochlorite
(·ClO−), hydrogen peroxide (H2O2), and hydroxyl radical (·OH-). The superoxide anion can
further combine with NO, forming the reactive compound peroxynitrite (ONOO·) and generating
a nitroso-redox imbalance (Hare and Stamler 2005). Additionally, peroxynitrite oxidizes
tetrahydrobiopterin (BH4), thereby leading to endothelial NOS (eNOS) uncoupling and
diminished NO production (Lin, Moran et al. 2005). These ROS are generated as intermediate
products in oxidative phosphorylation reactions and play a role in normal redox control of
physiological signaling pathways. They also act as important second messengers and
intracellular signaling molecules in cell growth, survival and apoptosis. However, excessive ROS
generation leads to oxidative stress, triggers cell dysfunction, lipid peroxidation, and DNA
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mutagenesis, among multiple additional tissue and cellular mechanistic altering functions
(Murdoch, Zhang et al. 2006).
The major source of ROS generation in the cardiovascular system is NADPH oxidase.
NADPH oxidase is composed of multiple subunits, including two membrane-bound subunits,
p22phox and gp91phox (also known as Nox2, or the homologues Nox1 and Nox4), and the
cytosolic subunits p47phox, p40phox, p67phox and Rac1 (a small G-protein) (Lassegue and
Clempus 2003; Lambeth 2004). Upon stimulation, the cytosolic subunits migrate towards the
plasma membrane bound subunits and become enzymatically active upon their unification,
ultimately yielding superoxide by the 1 electron reduction of oxygen using NADPH as the
electron donor: 2O2+NADPH

2O2–+NADP+ (Lambeth 2004). Other enzymatic sources of ROS

involved are xanthine oxidases, uncoupling of the mitochondrial respiratory chain, cytochrome
p450, and uncoupling of eNOS. ROS are physiologically produced, but during diseased states,
these sources become the main culprits of sustained cellular and tissue damage, especially during
the hypertensive state (Griendling, Sorescu et al. 2000; Harrison and Gongora 2009).
Within the cardiovascular system and during the pathogenesis of hypertension, the
balance between the oxidant and anti-oxidant systems tips in favor of the more deleterious
oxidative side. If left uncontrolled, it can elicit many changes in the various organ systems
required for cardiovascular homeostasis, including the heart, kidney and brain. It is here that over
a prolonged period of time, the oxidative unbalance leads to sustained oxidative stress, an
exasperated hypertensive response, and eventually, end-organ damage and death.
Redox Balance and Inflammation in Hypertension. The importance of redox signaling
mechanisms in the heart, kidneys and brain, and their contribution to end organ damage in
hypertension is a relatively new concept. It is of note that activated immune cells release large
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quantities of ROS, promoting regional oxidative stress. Oxidative stress may also contribute to
hypertensive risk by upregulating production of PICs such as TNF, IL-1β, IL-6, etc. and acute
phase proteins such as C-reactive protein (CRP), through activation of the transcription factor
NFκB (Barnes and Karin 1997; Himmelfarb 2004), all of which are involved in the hypertensive
response. Increased levels of circulating PICs lead to an increase in cytosolic ROS production
from sources such as NADPH oxidase. This increase in ROS can signal the mitochondria to
increase their ROS production, and can also trigger the phosphorylation of IκBα, which is
responsible for maintaining NFκB in its inactive form. Once the IκBα is phosphorylated, NFκB
is “activated” and translocates into the nucleus to facilitate the transcription of several PIC
geness, including TNF. This gene transcription will lead to further increases in circulating PICs,
thereby creating a vicious positive feed-forward cycle.
Not only does ROS activate NFκB, but several lines of in vitro experimental evidence
indicate that NFκB activation can also lead to ROS generation (Flohe, Brigelius-Flohe et al.
1997; Crack and Taylor 2005). NFκB activation can be triggered by the addition of H2O2 to
some cell types in the absence of a physiological stimulus, and NFκB activation is inhibited by a
broad range of antioxidants (Gloire, Legrand-Poels et al. 2006). Overexpression of copper/zinc
superoxide dismutase (CuZn-SOD) enhances NFκB activation by TNF, while overexpression of
catalase or of glutathione peroxidase attenuates NFκB activation by TNF (Sakon, Xue et al.
2003; Pham, Bubici et al. 2004; Gloire, Legrand-Poels et al. 2006). There is a bidirectional
interaction between oxidative stress and inflammation. H2O2 produced from the mitochondria
leads to NFκB activation in the cytosol and consequently to the production of PICs. Although the
response to oxidative stimuli is short-lived under normal conditions, it can lead to chronic
inflammatory responses when the oxidative stimuli are poorly controlled (Chung, Cesari et al.
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2009). Furthermore, induction of TNF can increase cellular ROS production, mainly via
activation of NADPH oxidase. Due to a positive feed-forward loop, this results in further
activation of NFκB and production of TNF (Mariappan, Soorappan et al. 2007; Csiszar, Wang et
al. 2008; Mariappan, Elks et al. 2009; Mariappan, Elks et al. 2010). The interaction between
oxidative stress and inflammation appears to play an important role in vascular, heart, kidney and
brain tissue inflammation and in the development of hypertension. Together, these data indicate
that NFκB is also a redox-responsive transcription factor. Thus, the role of inflammation in
hypertension cannot be overstated and must be accounted for when addressing the issue of ROS
in the pathogenesis of hypertension. Therefore, it is important to understand the PIC and RAS
mechanisms contributing to the generation of oxidative stress in hypertension, the effects of this
oxidative stress on hypertension, as well as possible therapeutic approaches towards alleviating
the oxidant component of the hypertensive state through PIC and RAS modulation.
THE BRAIN IN HYPERTENSION
Hypertension is a multifaceted disorder involving not only peripheral factors and organ
systems, but complex signaling mechanisms into and throughout the central nervous system
(CNS) (de Wardener 2001; Guyenet 2006; Peterson, Sharma et al. 2006; Harrison and Gongora
2009; Shi, Raizada et al. 2010). Over the past decade, multiple studies have confirmed the role
that central neurogenic mechanisms play in the maintenance and management of blood pressure
and volume homeostasis through modulation of the vasculature, heart and kidneys (Guyenet
2006). This includes, but is not limited to, modulation of sympathetic tone, water and salt
balance, and system wide regulation of circulatory hormonal release (de Wardener 2001). These
nuclei are situated throughout the forebrain, midbrain, and hindbrain regions, each with specific
and overlapping roles in cardiovascular homeostasis and response. These nuclei receive inputs
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from afferent signals via baro-, chemo-, and osmoreceptors located throughout the body, as well
as neural inputs from the circumventricular organs (CVOs), a specialized region of the brain that
lacks a fully developed blood brain barrier (BBB) and enables the brain to detect blood-borne
signaling hormones and blood osmolality levels through receptors protruding from this area
(Guyenet 2006; Peterson, Sharma et al. 2006). These CVOs, along with other cardio-regulatory
regions of the brain, are implicated in the maintenance of many experimentally observed forms
of hypertension (Harrison and Gongora 2009).
Mounting evidence indicates that the brain plays a major role in the pathogenesis of
hypertension and that neurogenic mechanisms are dominant in over 40% of essential
hypertensive patients (Esler and Kaye 2003; Hirooka 2008), and more specifically, that the
sympathetic nervous system (SNS) plays a major role in the pathogenesis of hypertension
(Guyenet 2006; Hirooka 2008). When acutely and chronically activated, the SNS can become
involved in 24-hour blood pressure patterns and the sustained progression of hypertension,
ultimately resulting in metabolic abnormalities, end-organ damage, and even death (Kishi,
Hirooka et al. 2001; Harrison and Gongora 2009). During the past several years, new evidence
has also emerged that clearly demonstrates the involvement of PICs, NFκB and ROS in the brain
in blood pressure regulation by serving as signaling/modulatory molecules within neurons of
cardiovascular regulatory centers and in the regulation of the SNS (Paravicini and Touyz 2006;
Peterson, Sharma et al. 2006). These components are linked to sympathetic modulation both
during physiological and pathophysiological functions.
The RAS and the Brain. The brain is capable of expressing all the genes that comprise the
components of the RAS, including renin, angiotensinogen, Ang I Ang II, Ang (1-7), ACE,
ACE2, AT1R, AT2R and the Mas receptor (Davisson 2003; Veerasingham and Raizada 2003;
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Xu, Sriramula et al. 2011). Recent data indicate that central AT1R up-regulation plays a critical
role in activating pre-sympathetic neurons residing in various cardio-regulatory centers in the
brain (Guyenet 2006). The enhancement of neuronal AT1R transcription appears to be a critical
mechanism of this central AT1R up-regulation. Several factors, including PICs, ROS and RAS
signaling affect AT1R expression and activity, which, in turn, modulates neuronal activity. The
pre-sympathetic actions of AT1Rs in CVD ultimately lead to enhanced sympathoexcitation and
controls many cardio-regulatory functions (Ganong 2000). AT1Rs are located directly on the
neurons, and when excited, drive post-sympathetic norepinephrine release to elicit cardiovascular
alterations (i.e. increased vasoconstriction, heart rate, renin release, etc.) (Davisson 2003).
The PVN and Hypertension. Within the brain, studies have demonstrated the location of AT1Rs
on many regions associated with systemic and cardiovascular homeostasis. It should also be
noted that several regions show a more pronounced effect of receptor activation in regulating
short- and long-term sympathetic regulation, including, but not limited to, the CVOs, the
hypothalamic PVN and the ventrolateral medulla (VLM) (Davisson 2003; Coote 2005). The
CVOs directly detect the presence of Ang II through AT1R activation, thus serving as a major
entry point for the Ang II signal into the brain. The PVN appears to be the main integrative site
of the many cardiovascular inputs to the CNS; it also has a large number of AT1Rs located
throughout its region (Dampney 1994; Francis, Weiss et al. 2001; Coote 2005; Kang, Ma et al.
2009). This site has direct projections to the pituitary gland and can increase ADH secretion, as
well as neurons that project to the adrenal glands and elicit aldosterone synthesis and secretion
(Coote 2005). Finally, the VLM is the main exit point of sympathetic neurons from the brain to
the spinal column and into the periphery, also receiving signals from the PVN (Dampney 1994).
Taken together, activation of AT1Rs can induce systemic pressor effects via the sympathetic
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nervous system, can blunt baroreceptor actions and signals, induce ADH synthesis and release,
as well as control salt and water appetite.

Figure 1.3. Schematic depicting the Ang II signaling pattern between the brain and the
periphery. Increased Ang II signals to the brain via the blood brain barrier, whereupon it
signals to various cardio-regulatory centers, such as the PVN. Local Ang II signaling
subsequently causes an imbalance in PICs, ROS and the RAS thereby perpetuating the
hypertensive state.

The proposed intracellular signaling mechanism whereby AT1R activation causes a
sympathetic response is unclear, but many studies have pointed to the role that PICs and ROS
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play in this pathway (Peterson, Sharma et al. 2006; Harrison and Gongora 2009). For example,
AT1R activation activates membrane NADPH oxidases to produce ROS such as superoxide and
hydrogen peroxide, and inhibits SODs. It is suspected that this NADPH oxidase activation goes
through a phospholipase D/protein kinase C phosphorylating pathway (Seshiah, Weber et al.
2002). However, other investigations outline a p38 MAPK and ERK1/2 pathway, or through PIC
activation of NFκB that increases ROS production (Chan, Hsu et al. 2005). Regardless, it is
abundantly apparent that the combination of PIC, RAS and ROS cross-talk and responses within
the brain drive the neurogenic portion of the hypertensive state.
Multiple regions within the brain have modulatory roles in the hypertensive response
such as the VLM, subfornical organ (SFO), supraoptic nucleus (SON), nucleus tractus solitarius
(NTS), area pastrema (AP) and organum vasculosum lamina terminalis (OVLT), but central
within these signaling sites is the hypothalamic PVN (Dampney 1994; Coote 2005; Kang, Ma et
al. 2009). Though much is known regarding autonomic regulation, the signaling pattern between
these sites is complex and still not clearly understood (Coote 2005; Guyenet 2006). In brief,
baroreceptor afferents and the vagus nerve signal the NTS of the medulla oblongata during
pressure changes. NTS axons project to the magnocellular neurons of the PVN (involved in
neuroendocrine control of ADH and fluid balance), while projections from the AP, OVLT and
SFO (CVO regions that sense blood-borne neuropeptides such as Ang II and PICs) synapse on
the parvocellular neurons of the PVN and the SON (Ericsson, Liu et al. 1995; Coote 2005).
These parvocellular neurons project into the VLM where the signal travels down the medial
column to regulate systemic sympathetic responses (Dampney 1994). These neuronal tracts
denote the central role that the PVN has in sympathetic regulation, body fluid homeostasis via
water and salt modulation, and the overall control of hypertensive responses. For instance,
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studies microinjecting Ang II into the PVN of rats raise mean arterial blood pressure, which is
attenuated following AT1R antagonism (Zhu, Patel et al. 2002; Zhu, Gao et al. 2004). Also,
chronic peripheral infusion of Ang II results in increased PIC, NFκB and ROS component
expression in the PVN (Kang, Ma et al. 2009). The combination of these results points to a
potential role that PICs, RAS and ROS in the PVN can play in contributing to the pathogenesis
of hypertension. Better understanding these central mechanisms may also outline new
pharmacological targets with which to dampen the debilitating effects of hypertension, making
its study paramount.
STATEMENT OF THE PROBLEM AND SPECIFIC AIMS
The role of inflammation in hypertension is evident. Increased concentrations of PICs,
ROS and RAS components are predominant during the pathogenesis of hypertension.
Systemically, these factors contribute to cardiovascular changes, including cardiac hypertrophy,
fibrosis and contractile dysfunction. Centrally, these same factors exacerbate those systemic
changes through neuronal modulation of sympathetic activity, especially within the PVN,
thereby altering pressure volume homeostasis during hypertension. Current therapeutic regimes
typically target components of volume regulation, peripheral adrenergic receptor activity, or of
the RAS. However, these options often fall short of controlling hypertension or the CVDs
associated with hypertension. Therefore, a deeper understanding of altering mechanisms of
hypertension is of pressing importance.
Recent evidence highlights the role that inflammation, specifically TNF, plays in
hypertension and regulating the RAS, but the understanding as to how inflammation as a whole
is regulated following Ang II or TNF activation, as well as the resultant consequences, is unclear.
Based upon the literature and work from our lab, we hypothesized that inflammatory regulation
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at the cytosolic and transcriptional level alters the systemic hypertensive response through
regulation of the transcription factor NFκB and the dysregulation of components of the RAS. We
tested this hypothesis in vivo through several sets of experiments. First, we needed to identfiy
how TNF infusion alone would modulate the RAS in the heart and contribute to the hypertensive
response. Second, we investigated the effect of chronic inhibition of histone modifications and
the resultant effects on heart inflammation and NFκB, and its effect on the hypertensive
response. Next, we hypothesized that central regulation of inflammation within the PVN,
through TNF and NFκB, alters local PIC, RAS and ROS responses in propagating the systemic
effects of the hypertensive state. Here we conducted a series of studies in which we centrally
inhibited TNF or NFκB to determine the functional role of brain or PVN inflammation in the
regulation of the RAS and in the perpetuation of the hypertensive response.
In order to explore these hypotheses, we preformed a series of in vivo experiments
integrated with cardiovascular surgical, physiological and molecular techniques to elucidate our
specific study aims:
Aim 1: Determine the role that systemic TNF infusion has on systemic cardiovascular,
RAS and ROS responses in adult rat heart tissues and in blood pressure regulation.
Aim 2: Determine the role that histone deacetylases have on systemic cardiovascular
NFκB, RAS and ROS responses in a chronically hypertensive rat model (spontaneously
hypertensive rats; SHR).
Aim 3: Determine the role that central TNF inhibition would have on PVN PICs and
RAS and ROS components in chronically Ang II-infused rats.
Aim 4: Determine the role that PVN specific NFκB has on regulating the RAS and ROS
responses in the Ang II-induced hypertensive response.
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CHAPTER 2
TUMOR NECROSIS FACTOR – INDUCED OXIDATIVE STRESS REGULATES
COMPONENTS OF THE RENIN-ANGIOTENSIN SYSTEM
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INTRODUCTION
Cardiovascular diseases are commonly associated with increased expression of proinflammatory cytokines (PICs), including hypertension (Phillips and Kagiyama 2002; Ferrario
and Strawn 2006). The renin-angiotensin system (RAS), the primary controlling mechanism in
blood pressure regulation, also plays a major role in modulating the hypertensive response.
Furthermore, studies from our lab and others have shown that in hypertension, PICs can lead to
an increase in reactive oxygen species (ROS) and further increases in PIC, ROS and RAS
transcription (Sriramula, Haque et al. 2008; Elks, Mariappan et al. 2009; Mariappan, Elks et al.
2009). Along with RAS components, PICs also activate hypertrophic mediators, which can result
in cardiac hypertrophy and altered cardiac remodeling and function, potentially via a ROSmediated mechanism (Tokuda, Kai et al. 2004; Kudo, Kai et al. 2009). Angiotensin II (Ang II),
the effector peptide of the RAS, has been shown to incite the synthesis and release of PICs such
as tumor necrosis factor-α (TNF), Interleukin (IL)-6 and chemokines (Funakoshi, Ichiki et al.
1999; Kalra, Sivasubramanian et al. 2002; Ruiz-Ortega, Ruperez et al. 2002), and both Ang II
and PICs can increase ROS, which individually and combined can contribute to cardiac
maladaptations, dysfunction and blood pressure response.
The actions of Ang II are typically understood through its classical pathway of
angiotensin converting enzyme (ACE) and Ang II-Type 1 receptors (AT1Rs), the prohypertensive/vasoconstrictive and deleterious ACE/Ang II/AT1R pathway. However, a recent
alternative axis of the RAS has been discovered that counteracts the actions of the prohypertensive RAS arm. This protective, anti-hypertensive/vasodilatory axis consists of ACE2,
Ang (1-7) and the Mas receptor, amongst others (Donoghue, Hsieh et al. 2000; Tipnis, Hooper et
al. 2000; Xu, Sriramula et al. 2011). Data suggests that the ACE2/Ang (1-7)/Mas arm may be
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downregulated by an increase in Ang II (Xu, Sriramula et al. 2011), but the manner in which this
dysregulation occurs, if through TNF, is unknown.
The PIC most central to the Ang II-driven hypertensive inflammatory responses is TNF, a
multifarious cytokine that plays an important and diverse role in physiological and
pathophysiological responses, including, but not limited to, inflammation, cell survival, growth,
differentiation and apoptosis (Mann 2002). It is well established that there is an existent crosstalk in hypertension between the RAS, especially Ang II, and TNF (Brasier, Li et al. 1996;
Sasamura, Nakazato et al. 1997; Kalra, Sivasubramanian et al. 2002; Arenas, Xu et al. 2004). We
have recently demonstrated, along with others, the integral manner that Ang II-induced TNF
functions to modulate blood pressure response and cardiac hypertrophy in Ang II-induced
hypertension, but if and how TNF alone can modulate these RAS arms is uncertain (Muller,
Shagdarsuren et al. 2002; Elmarakby, Quigley et al. 2006; Sriramula, Haque et al. 2008).
Early studies showed that the major source of vascular ROS is primarily NADPH oxidase
derived superoxide (Griendling, Minieri et al. 1994; Mohazzab, Kaminski et al. 1994), which can
be regulated by multiple mediators, including cytokines (Paravicini and Touyz 2008; Harrison
and Gongora 2009). Moreover, an increased expression of NADPH oxidase was noted in cardiac
tissue in Ang II-induced hypertensive animal models (Li, Gall et al. 2002; Paravicini and Touyz
2008). The NADPH oxidase subunit gp91phox (Nox2) is central to Ang II-induced cardiac
hypertrophy (Bendall, Cave et al. 2002; Li, Gall et al. 2002). In Ang II-infused animal models
and SHR rats, NADPH activity is increased and ROS generation is enhanced and these processes
are mediated through AT1Rs and are associated with the overexpression of vascular and cardiac
NADPH oxidase subunits (Cifuentes, Rey et al. 2000; Heymes, Bendall et al. 2003; Kakishita,
Nakamura et al. 2003). These studies support a role for NADPH oxidase-derived superoxide and
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increased oxidative stress in the pathogenesis of Ang II-induced hypertension. Within the heart,
ROS signaling elicits numerous responses, including cardiac hypertrophy and fibrosis, which can
be triggered by TNF and can be inhibited through the use of anti-oxidants (Seddon, Looi et al.
2007; Paravicini and Touyz 2008). Furthermore, sub-pressor doses of Ang II can also induce
cardiac hypertrophy and interstitial fibrosis in mice, which can also be blunted in hearts lacking
gp91phox (Bendall, Cave et al. 2002). Interstitial cardiac fibrosis and remodeling was also
inhibited in Nox2 knockout mice subjected to aortic banding, Ang II or aldosterone infusion, or
in animals treated with apocynin or diphenylene iodinium (NADPH oxidase inhibitors) (Bendall,
Cave et al. 2002; Park, Park et al. 2004; Touyz, Mercure et al. 2005; Grieve, Byrne et al. 2006;
Johar, Cave et al. 2006; Paravicini and Touyz 2008).
The signaling pattern from Ang II to TNF is evident, but how TNF alone can act, if at all,
on components of the RAS and on blood pressure response is uncertain. With these
considerations, we hypothesized that daily TNF injections would contribute to cardiac tissue
RAS modulation and blood pressure response, possibly through a ROS mechanism. In order to
conduct this study, we injected TNF for 5 consecutive days, during which time we recorded
blood pressure via radio-telemetry probes and conducted echocardiographic assessment of
cardiac function. At the conclusion of the study, left ventricle (LV) tissue was collected for
assessment of RAS and ROS component expression. For determination of the role of ROS as a
signaling mediator between TNF and RAS component expression, along with TNF treatment, we
simultaneously administered either Tempol, a superoxide dismutase (SOD) mimetic, or
etanercept, a soluble TNF receptor mimetic. While neither TNF nor the treatments had any effect
on blood pressure regulation, alterations were observed in cardiac function and RAS component
expression, ultimately demonstrating that the TNF can increase cardiac dysfunction (via its
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function as a negative inotrope) and pro-hypertensive/vasoconstrictive RAS components, and
decrease anti-hypertensive RAS component expression, which was reversed following Tempol
or etanercept treatment. This study also demonstrates that ROS are a signaling mediator between
TNF and the RAS and cardiac changes. More importantly, it shows that TNF can differentially
regulate the damaging and protective arms of the RAS, potentially via a ROS mechanism, which
may be a tipping point in the hypertensive response.
MATERIALS AND METHODS
Animals. Adult male Sprague-Dawley rats (250-350 grams) were used in this study. Animals
were housed in a temperature-controlled room (25 ± 1oC) and maintained on a 12:12 hour
light:dark cycle with free access to water and food. All animal and experimental procedures were
reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at
Louisiana State University in compliance with NIH guidelines.
Experimental Protocol. The rats were implanted with radio-telemetry transmitters to measure
blood pressure, and injected daily with TNF (40µg/kg, i.p.) dissolved in saline or saline alone for
5 consecutive days. This TNF dose was based on unpublished dose-response studies as well as
previous publications from our laboratory and others (Michie, Sherman et al. 1989; Bozkurt,
Kribbs et al. 1998; Mariappan, Soorappan et al. 2007; Mariappan, Elks et al. 2009).
Simultaneously, a subset of TNF and saline-treated rats received either Tempol (Temp;
300µmol/kg, p.o.), a SOD mimetic, or Etanercept (ETN; 1mg/kg/day, s.c.), a soluble TNF
receptor mimetic. Saline-treated rats receiving Temp or ETN were unchanged from saline-treated
controls and as such were combined together for the final analysis. The study consisted of four
experimental groups: 1) Controls (saline alone, saline+Tempol and saline+etanercept); 2) TNF;
3) TNF+Temp; and 4) TNF+ETN. Echocardiographic assessment was carried out at baseline and
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at the conclusion of the study. After five days, the rats were euthanized and the hearts were
removed for further analysis.
Blood Pressure Measurement. Blood pressure was measured continuously in conscious rats
implanted with radio-telemetry transmitters (Model TA11PA-C40, Data Sciences International,
St. Paul, MN). Rats were anesthetized with a ketamine (90 mg/kg) and xylazine (10 mg/kg)
mixture (i.p.) and placed dorsally on a heated surgical table. An incision was made on the ventral
surface of the left leg, the femoral artery and vein were exposed and bluntly dissected apart. The
femoral artery was ligated distally, and another was used to temporarily interrupt the blood flow.
The catheter tip was introduced through a small hole in the femoral artery, advanced 6 cm into
the abdominal aorta such that the tip was distal to the origin of the renal arteries, and secured into
place. The probe body was placed into the abdominal cavity and secured to the abdominal wall.
The abdominal musculature was sutured and the skin layer closed following implantation. Rats
received benzathine penicillin (30000 U, i.m.) and buprenorphine (0.1 mg/kg, s.c.) immediately
following surgery and 12hr postoperatively and allowed to recover for seven days.
Echocardiographic Assessment of LV Hypertrophy. Echocardiography was obtained at
baseline, and repeated at the end of the treatment period. Echocardiogram was performed as
described previously (Mariappan, Elks et al. 2009). Briefly, transthoracic echocardiography was
performed under isoflurane anesthesia, using a Toshiba Aplio SSH770 (Toshiba Medical, Tustin,
California) fitted with a PST 65A sector scanner (8 MHz probe) which generates twodimensional images at a frame rate ranging from 300-500 frames per second. Left ventricle wall
and chamber parameters, fractional shortening (%FS) and Tei index were measured and
calculated to assess cardiac hypertrophy and cardiac function.
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Detection of Total ROS and Superoxide (O2•−) in LV Heart Tissue. One of the most sensitive
and definitive methods of superoxide production is electron spin resonance (EPR). In this study,
we utilized an established technique for total ROS detection in tissue using EPR and spin traps
(Mariappan, Elks et al. 2009). Different spin probes were used for the EPR studies. 1-hydroxy-3methoxycarbonyl-2, 2, 5, 5-tetramethylpyrrolidine (CMH) was used to measure the O2•− levels.
All ESR measurements were performed using an EMX EPR eScan BenchTop spectrometer and
super-high quality factor (Q) microwave cavity (Bruker Company, Germany). Sample
Preparation for EPR Studies: The dissected LV tissue from each animal was placed into a 24well plate containing Kreb’s HEPES buffer (KHB) (20mM, pH 7.4). Tissue pieces were then
washed twice with the same buffer to remove any trace contamination. Samples were then
incubated at 37oC with specific spin probes for 30 minutes. Total tissue ROS production: Total
ROS was determined as previously described (Mariappan, Elks et al. 2009). Tissue pieces were
incubated at 37oC with CMH (200 μM) for 30 minutes. Aliquots of the incubated probe media
were then taken in 50 μl glass capillary tubes (Noxygen Science Transfer and Diagnostics,
Elzach, Germany) for determination of total ROS production, under the following EPR settings:
field sweep 50 G; microwave frequency 9.78 GHz; microwave power 20 mW; modulation
amplitude 2 G; conversion time 327 ms; time constant 655 ms; receiver gain 1 x 105. For
superoxide production, samples were pre-incubated at 37oC with PEG-SOD (50 U/ml) for 30
minutes, then CMH (200uM) for an additional 30 minutes. Aliquots of the incubated probe
media were taken in 50 μl glass capillary tubes for determination of total superoxide production.
Addition of PEG-SOD to CMH allowed competitive inhibition of the O2•−-CMH oxidation
reaction by the quenching of O2•− radicals. Since it is cell permeable, PEG-SOD can
competitively inhibit the CMH-O2•− interaction both intra-cellularly and extra-cellularly, thus
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allowing accurate measurement of total tissue O2•- production. To determine actual total tissue
superoxide production, the values obtained from incubation with PEG-SOD and CMH were
subtracted from the values obtained from incubation with CMH only.
RNA Isolation and Real-Time RT-PCR. Total RNA was extracted from the LV using TRI
reagent (Invitrogen), and cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad) as
previously described (Guggilam, Haque et al. 2007; Sriramula, Haque et al. 2008). The mRNA
expression levels of gp91phox, angiotensinogen, renin, angiotensin converting enzyme (ACE),
ACE2, AT1R and the Mas receptor were determined using previously published specific custom
made primers (Guggilam, Haque et al. 2007; Sriramula, Haque et al. 2008; Agarwal, Haque et al.
2009; Elks, Mariappan et al. 2009; Mariappan, Elks et al. 2009). GAPDH was used as the
housekeeping gene. Real-time RT-PCR (qRT-PCR) was performed in 384 well PCR plates using
Bio-Rad PCR Master Mix (The iTaq SYBR™ Green Supermix with ROX) and the ABI Prism
7900 sequence detection system (Applied Biosystems). The PCR cycling conditions were as
follows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles (15 s at 95°C, 1 min, at 60°C).
A dissociation step (15 s at 95°C, 15 s, at 60°C and 15 s at 95°C) was added to check the melting
temperature of the specific PCR product.
Western Blot. Protein was extracted from LV samples in ice-cold buffer (10mM Tris-HCl, pH
7.4, 1mM EDTA, 1% Nonidet P-40, 0.1% sodium deoxycholate, and 0.1% SDS) containing a
protease inhibitor cocktail (Roche). The protein content in the supernatant was determined using
a detergent-compatible protein assay (Bio-Rad). Protein samples (25μg) were resolved in 10%
SDS-polyacrylamide gel. The protein expression of gp91phox and AT1R in the heart was
analyzed by western blot as previously described (Sriramula, Haque et al. 2008) with the use of
anti-gp91phox, anti-AT1R (Abcam) and the Mas receptor (Santa Cruz) antibody (1:200 dilution).
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Bands were normalized to α-Actinin or GAPDH (Santa Cruz). Bands were analyzed for
graphical and statistical densitometric representation using ImageJ.
Measurement of Plasma TNF. At the end of the study, blood was collected in chilled EDTA
tubes, plasma was separated and stored at -80°C until assayed. Circulating levels of TNF were
quantified in the plasma using a commercially available rat TNF ELISA kit (Biosource,
Camarillo, CA) according to manufacturer’s instructions.
Measurement of Plasma Catecholamines. At the end of the study, blood was collected in
chilled EDTA tubes, plasma was separated and stored at -80°C until assayed. Circulating levels
of norepinephrine (NE) and epinephrine (EPI) were measured using high performance liquid
chromatography (HPLC). Plasma samples were prepared by adding activated alumina, Tris
buffer, EDTA and internal standard DHBA, along with 0.5 ml of rat plasma. The samples were
centrifuged and the supernatant was separated and rinsed 2x in ultra pure water and filtered
through a Millipore filter (Ultrafree MC UFC30GV00, Millipore Corp.). Prepared samples were
then filtered and injected into an Eicom HTEC-500 system fitted with an HPLC-ECD, as
previously described (Guggilam, Haque et al. 2007).
Localization of Ang II by Immunofluorescence. Heart tissues were prepared as previously
described (Guggilam, Haque et al. 2007). The sections were treated with primary antibody
against Ang II (1:500 dilution, anti-goat) (Santa Cruz). Negative control sections were incubated
with secondary antibody alone.
Statistical Analysis of Data. All results are expressed as mean±SEM. For statistical analysis of
the data, student’s t test, one-way ANOVA or repeated measures ANOVA followed by
Bonferroni’s post hoc test was performed using GraphPad Prism version 5.0 for Windows
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(GraphPad Software, San Diego California, USA) to determine differences among groups. A
value of p<0.05 was considered statistically significant.
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Figure 2.1 Effects of TNF on circulating TNF, mean arterial blood pressure (MAP) and
heart weight/body weight (HW/BW). Plasma TNF concentration were elevated after 5
consecutive days of TNF injection versus controls and co-administration of Tempol
(TNF+Temp) or etanercept (TNF+ETN) (A). MAP was unaffected by TNF alone or in
TNF+Temp or TNF+ETN groups throughout the study period (B). HW/BW ratio as assessed
upon sacrifice shows an increase in cardiac mass after 5-day TNF treatments versus controls
(C). Tempol and etanercept reversed this increase in cardiac mass. n=9-10 per group, #p<0.05
vs Control, *p<0.05 vs TNF.

RESULTS
Daily TNF Injections have no Effect on Blood Pressure but alters Cardiac Function in
Treated Rats. The effect of daily TNF injections was examined at the conclusion of the 5-day
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study period to determine TNF plasma concentrations (Figure 2.1A). Using a TNF ELISA kit,
plasma concentrations were, as expected, much higher in TNF-treated as compared to controls
(7.61±0.53 v 0.65±0.22 pg/ml, respectively; p<0.05). These circulating levels of TNF were
reduced following Tempol (2.58±0.36 pg/ml; p<0.05) or etanercept (4.3±0.48 pg/ml; p<0.05) coadministration with TNF. This demonstrates that the TNF injections induced increases in
endogenous TNF. The endogenously produced TNF was also reduced following ROS/superoxide
reduction, thereby linking the TNF-induced TNF signal propagation to ROS intermediaries.
Table 2.1. Effects of TNF on cardiac function as assessed by echocardiography.
Table 2.1
Control
TNF
TNF+Temp
TNF+ETN
n
9
10
10
10
#
IVSTd (mm)
1.36±0.02
1.59±0.05
1.37±0.05*
1.41±0.03*
IVSTs (mm)
2.26±0.03
2.48±0.12
2.50±0.06
2.25±0.03
LVIDd (mm)
6.57±0.08
7.10±0.21
7.31±0.13
7.28±0.13
#
LVIDs (mm)
5.27±0.10
5.69±0.18
5.06±0.13*
4.78±0.15*
LVPWTd (mm)
1.37±0.11
1.57±0.07
1.38±0.03
1.38±0.03
LVPWTs (mm)
2.25±0.13
2.15±0.06
2.25±0.16
2.15±0.11
#
%FS
55.2±1.92
39.7±0.95
50.2±1.12*
43.8±0.77
#
Tei
0.29±0.03
0.38±0.11
0.30±0.02*
0.32±0.01
#
HR
327±7.46
366±10.1
329±3.78*
337±4.68*
IVSTd/s, interventricular septal thickness at end-diastole and end-systole, respectively;
LVIDd/s, left ventricular internal diameter at end-diastole and end-systole, respectively;
LVPWTd/s, left ventricular posterior wall thickness at end-diastole and end-systole,
respectively; %FS, fractional shortening; HR, heart rate; n=9-10 in each group, #p<0.05 vs
Control, *p<0.05 vs TNF.

To assess the effect of 5-day TNF injections on mean arterial pressure (MAP), blood
pressure was measured using a radio-telemetry system. There was no change in MAP from
baseline over the 5-day TNF injection period (Figure 2.1B). Moreover, TNF+Temp and
TNF+ETN had no effect on MAP versus the saline-treated controls, with all rat groups
maintaining a MAP between 105-112 mmHg during the course of the study. Interestingly,
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though there were no appreciable differences in the MAP, the heart weight/body weight
(HW/BW) ratio was increased in TNF-treated rats versus controls (3.2±0.07 v 2.9±0.05 g/kg,
respectively; p<0.05), which was reversed following Tempol (2.85±0.05 g/kg; p<0.05) and
Etanercept (2.94±0.04 g/kg; p<0.05) treatments (Figure 2.1C). Furthermore, interventricular
septal thickness at end-diastole (IVSTd) was significantly increased, while IVST in end-systole
(IVSTs) followed a similar trend (Table 2.1), confirming the HW/BW data and indicating TNFinduced cardiac hypertrophy. Also noted was that TNF treatments, possibly via its function as a
negative inotrope, reduced %FS and raised HR and the Tei index, signaling cardiac dysfunction.
TNF Increases Total ROS and gp91phox in the LV of TNF-Treated Rats. As TNF is often
associated with increases in ROS, both
Total ROS

total ROS and superoxide as assessed

of gp91phox (Figure 2.3) were
examined in the LV. TNF-treated rats

uM/mg protein/min

by EPR (Figure 2.2) and the expression

0.4

#

Control
TNF
TNF+Tempol
TNF+Etanercept

0.3

*#

0.2

*#

0.1
0.0

experienced a significant increase in
Superoxide

total ROS and superoxide when

0.15

Control
TNF
TNF+Tempol
TNF+Etanercept

compared to saline-infused control rats
(total ROS: 0.35±0.006 v 0.11±0.006
mM/mg protein/min, respectively;

uM/mg protein/min

#
0.10

0.05

*

*

0.00

p<0.05; and superoxide: 0.122±0.007 v
0.021±0.006 mM/mg protein/min,
respectively; p<0.05). TNF+Temp and
TNF+ETN normalized these ROS

Figure 2.2. Effect of TNF on ROS. Total ROS and
superoxide as measured by electron paramagnetic
spin resonance (EPR) were increased in 5-day
TNF-treated rats. This was reduced in TNF+Temp
and TNF+ETN groups after 5 days. n=6 in each
group, #p<0.05 vs Control, *p<0.05 vs TNF.
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increases (total ROS reduced to: 0.19±0.003 and 0.16±0.015 mM/mg protein/min, respectively;
p<0.05; and superoxide reduced to: 0.024±0.005 and 0.035±0.005 mM/mg protein/min,
respectively; p<0.05). Furthermore, the mRNA expression of gp91phox, the major catalytic
subunit of NADPH oxidase and a major ROS contributor, was increased in TNF-treated rats
versus the controls (Figure 2.3A). This was reduced in TNF+Temp and TNF+ETN rats. The
reduction in protein expression was further confirmed by western blot of the LV tissue (Figure
2.3B). These results indicate that treatment with Tempol and Etanercept had beneficial effects in
reducing TNF-induced oxidative stress in the LV heart tissue in TNF-infused rats.

A

gp91phox

mRNA Expression
(fold increase)

5

Control
TNF
TNF+Tempol
TNF+Etanercept

#

4
3

*

*

2
1
0

Control

B

TNF

TNF+Temp TNF+ETN

gp91phox Densitometry
60

Arbitrary Units

#
40

*

*

Control
TNF
TNF+Tempol
TNF+Etanercept

20

0

Figure 2.3. Effects of TNF on gp91phox. The catalytic subunit of NADPH oxidase,
gp91phox, was assessed via RT-PCR (A) and western blot (B). Both mRNA and protein
showed a similar pattern of increase in TNF-treated rats versus controls. The TNF-induced
changes were reduced following Tempol or etanercept co-administration. n=6-8 in each
group, #p<0.05 vs Control, *p<0.05 vs TNF.
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Components of the RAS Are Altered in the LV Following TNF Injections. In an attempt to
understand the link between the RAS and inflammation, several components of the RAS were
measured. The mRNA

#
3
2

*
*

1

mRNA Expression
(fold increase)

RAS components

4

4

mRNA Expression
(fold increase)

hypertensive/vasoconstrictive

Renin

Angiotensinogen

expression of the pro-

3

#

2

*

*

Control
TNF
TNF+Tempol
TNF+Etanercept

1
0

0

angiotensinogen, renin, ACE
AT 1R

ACE

increased following 5 days of

5

#

4

2

*

*

mRNA Expression
(fold increase)

and AT1R (Figure 2.4) are

mRNA Expression
(fold increase)

6

#

4
3

*
2

Control
TNF
TNF+Tempol
TNF+Etanercept

*

1
0

0

TNF treatment when compared
to controls, while the antihypertensive/vasodilatory
components ACE2 and the
Mas receptor were decreased
(Figure 2.6A). These trends

Figure 2.4. Effects of TNF administration on prohypertensive components of the RAS system. mRNA
expression for angiotensinogen, renin, angiotensin
converting enzyme (ACE) and AT1R all followed similar
patterns in the left ventricular tissues of treated rats. After 5
days, TNF injections increased these pro-hypertensive
components of the RAS versus controls. These increases
were normalized in TNF+Temp and TNF+ETN groups.
n=6-8 in each group, #p<0.05 vs Control, *p<0.05 vs TNF.

were reversed following treatment with Tempol or etanercept. Moreover, the protein levels of
AT1R and the Mas receptor as measured via western blot followed similar patterns to their
respective mRNA expressions, (Figure 2.5A, 2.6B). The levels of Ang II were further assessed
within the LV tissues using immunofluorescence. Ang II was similarly increased in TNF-treated
rats, but decreased in TNF+Temp and TNF+ETN rats (Figure 2.5B). This indicates that TNF
differentially alters injurious and protective RAS component expression within cardiac tissue,
which can be reversed following TNF or superoxide inhibition.
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Circulating Catecholamines Increase in TNF-Infused Rats. To assess the effect of daily TNF
injections on catecholamine release, circulating plasma NE and EPI were determined by HPLC
(Figure 2.7). TNF injections increased NE and EPI versus the control rats (1341±53.9 v
704.1±85.3 pg/ml and 459±40.7 v 185.7±12.4 pg/ml, respectively; p<0.05). These elevated
levels were decreased in TNF+Temp and TNF+ETN groups, signifying that TNF plays a role,
possibly through a RAS and ROS-mediated mechanisms, in elevating circulating catecholamines
and contributing to increased sympathetic activity, cardiac dysfunction and remodeling.

Control

A

TNF

TNF+Temp

TNF+ETN

AT 1R Densitometry
80

Arbitrary Units

#
60

*

*

Control
TNF
TNF+Tempol
TNF+Etanercept

40
20
0

B
Control

TNF

TNF+Tempol

TNF+Etanercept

Figure 2.5. Effects of TNF on AT1R protein expression and Ang II in left ventricular
tissues. Western blot and densitometric analysis reveals that similar to the mRNA expression
of AT1R, TNF increases its abundance when compared to controls (A). Likewise, Tempol or
etanercept attenuated these changes. Immunofluorescence (Original magnification x20)
staining of Ang II in cardiac tissue sections shows an increase in Ang II in the TNF-treated
rats (B). Co-administration with Tempol or etanercept eliminated this increase in Ang II
within the heart. n=6-8 in each group for AT1R protein, n=3-4 for immunofluorescence
images, #p<0.05 vs Control, *p<0.05 vs TNF.
46

DISCUSSION
The major findings in this study are as follows: 1) TNF injections for 5 days had no effect
on mean arterial blood pressure, but TNF did increase cardiac hypertrophy and negatively altered
cardiac function as seen with a reduction in fractional shortening and an increase in the Tei
index; 2) TNF injections increased total ROS and superoxide in the LV of treated rats; 3) TNFinfused rats showed an
ACE2

A
2.0
mRNA Expression
(fold increase)

elevation in pro-hypertensive/
vasoconstrictive RAS
component expression and a

1.5

*

*

*

*
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TNF+Etanercept
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#
0.5
0.0

decrease in anti-
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mRNA Expression
(fold increase)

1.5

hypertensive/vasodilatory RAS
component expression, as well
as an increase in the circulating

and 4) TNF-infused rats treated

0.5

#

0.0

B

catecholamines NE and EPI;

1.0

Control
TNF
TNF+Tempol
TNF+Etanercept

Control

TNF

TNF+Temp

TNF+ETN

Mas
GAPDH

with Tempol or Etanercept
prevented these changes
observed following TNF
injection alone. These findings
suggest that TNF can act on the
opposing components of the
RAS within the LV, possibly

Figure 2.6. Effects of TNF on ACE2 and Mas receptor
expression in left ventricular tissues. The mRNA
expression of ACE2 and Mas decreases following TNF
injection when compared to controls (A). Tempol or
etanercept reversed these changes and returned them to
normal levels. Western blot against the Mas receptor in
cardiac tissues shows a decrease in the protein levels in
TNF-treated rats (B). Co-administration with Tempol or
etanercept reversed this decrease within the heart. n=6-8 in
each group for AT1R protein, n=3-4 for
immunofluorescence images, #p<0.05 vs Control, *p<0.05
vs TNF.

through a ROS-driven
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mechanism, and negatively affect cardiac function and cardiac mass while not effecting pressure
responses in treated rats.
Hypertension is increasingly accepted as involving an inflammatory component (Ferrario
and Strawn 2006; Sriramula, Haque et al. 2008; Cardinale, Sriramula et al. 2010). Furthermore,
the RAS plays a key role in the development and maintenance of hypertension (Brunner 2001;
1500

#

*

1000

pg/mL

Control
TNF
TNF+Tempol
TNF+Etanercept

Ruiz-Ortega, Lorenzo et al. 2001), and
Ang II, the effector peptide of the RAS,
has been shown to stimulate the

*
###

production and release of PICs such as

#

500

##

*
*

TNF, IL-6 and chemokines (Funakoshi,
Ichiki et al. 1999; Kalra,

0

Norepinephrine

Epinephrine

Sivasubramanian et al. 2002; RuizFigure 2.7. Effects of TNF on circulating
catecholamines. The circulating plasma
norepinephrine (NE) and epinephrine (EPI) levels
were determined by HPLC. TNF injection
increased NE and EPI versus controls, which was
decreased in TNF+Temp and TNF+ETN groups.
n=6-8 in each group, #p<0.05 vs Control, *p<0.05
vs TNF.

Ortega, Ruperez et al. 2002).
Components of the ACE2/Ang (17)/Mas RAS axis are also downregulated
during hypertensive disease progression
(Xu, Sriramula et al. 2011). Recently,

work from our lab demonstrated the involvement of Ang II-induced TNF in the Ang II-mediated
effects on the hypertensive response (Sriramula, Haque et al. 2008). Changes observed included
an increase in salt appetite and water retention, therefore unbalancing systemic volume
homeostasis, as well as increased cardiac hypertrophy and the overall perpetuation of the
hypertensive state. Others have also observed the existence of a potential cross-talk between the
RAS and TNF. In vitro studies showed the production of TNF following cardiomyocyte and
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fibroblast cell culture treatments with Ang II, and that neonatal rat cardiac fibroblast culture
treatments with TNF caused an increase in AT1R expression (Gurantz, Cowling et al. 1999;
Yokoyama, Sekiguchi et al. 1999; Kalra, Sivasubramanian et al. 2002). In vivo studies have also
linked PICs and the RAS, including demonstrating that chronic AT1R inhibition in hypertensive
and heart failure patients decreased circulating TNF and that TNF blockade prevented renal
damage and lowered blood pressure in a genetic model of hypertensive rats (Cottone, Vadala et
al. 1998; Tsutamoto, Wada et al. 2000; Muller, Shagdarsuren et al. 2002; Elmarakby, Quigley et
al. 2006). Combined, these changes suggest an intimate connection between the RAS and PICs,
especially TNF, in the hypertensive response, in that Ang II activates TNF, which is speculated
to further increase pro-hypertensive RAS expression. In this study, we looked at the possible
reverse signaling pattern of the afore mentioned mechanism. Though not altering blood pressure,
we show that five days of continuous TNF injections can differentially regulating RAS
components such as Ang II, ACE2, AT1 and the Mas receptors by decreasing the vasodilatory
components and increasing the vasoconstrictive components of the RAS. In time, these RAS
component dysregulations, especially the increase in Ang II, could lead to arterial pressure
increases, but the current study was not carried out to that point.
The role of ROS in the pathogenesis of hypertension is well established in many
experimental hypertensive models (Harrison and Gongora 2009). Activation of NADPH oxidase
is regulated by many vasoactive hormones, cytokines, growth factors (platelet-derived growth
factor, transforming growth factors, etc.) and mechanical stimuli such as shear stress and stretch
(Paravicini and Touyz 2008; Harrison and Gongora 2009). Compared to their normotensive
controls, SHR and DOCA salt-sensitive rats show an increase in the production of superoxide in
cardiac, renal and vascular tissues, primarily through NADPH oxidase activity (Zalba, Beaumont
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et al. 2000; Zhang, Griendling et al. 2005). As seen in the current study, increased ROS
production, with an increased expression of NADPH oxidase, was noted in cardiac tissue in both
a pressure overload model of cardiac hypertrophy and in Ang II hypertensive animal models (Li,
Gall et al. 2002; Paravicini and Touyz 2008). The role of the gp91phox subunit (Nox2) of
NADPH oxidase in Ang II-induced cardiac hypertrophy is pivotal. Studies conducted on mice
lacking gp91phox showed that myocardial NADPH oxidase and superoxide levels were not as
elevated in these animals as compared to their wild-type controls (Bendall, Cave et al. 2002),
supporting the fact that NADPH oxidase is the major source of ROS in cardiomyocytes in
hypertrophy due to a chronically increased blood pressure, which can progress to heart failure
(Li, Gall et al. 2002). In Ang II-infused animal models and SHR rats, NADPH activity is
increased and ROS generation is enhanced; these processes are mediated through AT1Rs and
associated with overexpression of vascular and cardiac NADPH oxidase subunits (Cifuentes,
Rey et al. 2000; Heymes, Bendall et al. 2003; Kakishita, Nakamura et al. 2003). An in vitro
study using cardiomyocyte cell cultures, Ang II stimulation increases both mRNA and protein
expression of gp91phox (Griendling, Sorescu et al. 2000). These studies, combined with the
current data depicting an elevation in gp91phox expression and total ROS and superoxide,
supports a role for NADPH oxidase-derived ROS and increased oxidative stress in the
pathogenesis of Ang II-induced hypertension through a TNF-driven mechanism, but the role of
ROS on the protective ACE2/Ang (1-7)/Mas RAS axis is vague.
Within the heart, ROS signaling elicits numerous responses, including cardiac
hypertrophy (Seddon, Looi et al. 2007; Paravicini and Touyz 2008), though its effects by and
through the separate arms of the RAS are only now coming under scrutiny. Oxidative stress is
also a well known profibrotic mediator in many tissue systems, including the heart. Moreover,
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excessive interstitial fibrosis is an injurious aspect of cardiac hypertrophy. These changes, in
turn, cause the slow progression of cardiac maladaptive remodeling and dysfunction, as observed
here following TNF injection and a subsequent decrease in fractional shortening and an increase
in the Tei index. In cardiomyocyte cultures, Ang II, endothelin 1, NE, TNF and mechanical
stretch can all induce cellular hypertrophy, including an increase in ROS production (Cave,
Grieve et al. 2005), which can be inhibited through the use of antioxidants. Ang II-treated
primary rat cardiomyocytes also demonstrated increased Rac1 (a small signaling G protein)
activation, superoxide production, and cell hypertrophy. These changes were blocked by
adenoviral introduction of dominant negative Rac1, CuZn-SOD and by small interfering RNA
(siRNA) directed to the gp91phox subunit of NADPH oxidase, suggesting that Ang II-activation
of gp91phox contributes to cardiac hypertrophy (Hingtgen, Tian et al. 2006). However, subpressor doses of Ang II also induce cardiac hypertrophy and interstitial fibrosis in mice, which
can also be blunted in hearts lacking gp91phox (Bendall, Cave et al. 2002). Interstitial cardiac
fibrosis and remodeling was also inhibited in Nox2 knockout mice subjected to aortic banding,
Ang II or aldosterone infusion, or in animals treated with apocynin or diphenylene iodinium
(NADPH oxidase inhibitors) (Bendall, Cave et al. 2002; Park, Park et al. 2004; Touyz, Mercure
et al. 2005; Grieve, Byrne et al. 2006; Johar, Cave et al. 2006; Paravicini and Touyz 2008).
Similarly, TNF alone caused cardiac alterations such as cardiac hypertrophy, decreased
fractional shortening and an increased Tei index, but following treatment with Tempol and
etanercept, these changes were reversed. Furthermore, NE and EPI, molecules that can
participate in altered cardiac function and remodeling (Badenhorst, Veliotes et al. 2003; Cave,
Grieve et al. 2005), as well as in the generalized sympathetic drive associated with hypertension,
was increased in TNF-infused rats, but decreased following Tempol or etanercept treatment. This
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data reinforces the role that ROS plays in the TNF-induced signaling pattern for increased
cardiac dysfunction and maladaptive alterations, possibly through the dysregulation of RAS
component expression.
It is well understood that the RAS and Ang II can increase the production of PICs and
contribute to the hypertensive state, and that blocking the PIC TNF can prevent some of the
deleterious changes associated with hypertension and the ACE/Ang II/AT1R RAS axis
(Funakoshi, Ichiki et al. 1999; Kalra, Sivasubramanian et al. 2002; Muller, Shagdarsuren et al.
2002; Ruiz-Ortega, Ruperez et al. 2002; Elmarakby, Quigley et al. 2006). The suggested
mechanism potentially involves a positive feed-forward system whereby Ang II increases TNF
and ROS, which in turn further increases injurious ACE/Ang II/AT1R RAS axis components,
and decreases protective ACE2/Ang (1-7)/Mas RAS components. Therefore, we aimed to
determine if administration of TNF alone could regulate components of the RAS and if so, was
this mechanism achieved through modulation of ROS. As detailed above, TNF injection
increased components of the deleterious axis of the RAS including angiotensinogen, ACE, Ang
II and the AT1R. TNF injection also increased gp91phox, total ROS and superoxide, and
decreased the protective RAS components ACE2 and the Mas receptor. These changes were
reversed following administration of the TNF receptor mimetic etanercept, indicating that the
TNF-driven pathway required the additional production of endogenous TNF, and the use of the
SOD mimetic Tempol demonstrates that the TNF-induced TNF-driven pathway also requires
ROS, especially superoxide, to contribute to the dysregulation of the individual RAS arms and
the propagation of mediators that can contribute to the hypertensive state. In conjunction with the
understanding that Ang II can cause an increase in TNF and the studies detailing that use of PIC
and ROS inhibitors can reduce the hypertensive response, we demonstrate here that the ROS

52

involved appears to evolve through a TNF mechanism, therefore highlighting the Ang
II/TNF/ROS pathway rather than an Ang II/ROS/TNF pathway, and that this in turn reduces the
protective RAS axis (ACE2/Ang (1-7)/Mas) while upregulating the more injurious aspects of the
pro-hypertensive/vasorestrictive RAS arm (ACE/Ang II/AT1R). This study underscores the role
that TNF plays in the ROS-induced dysregulation of the RAS and the ROS driven mechanism
behind TNF-induced cardiac dysfunction, spotlighting the role that PICs, such as TNF, may play
in the differential RAS regulation in the pathogenesis of the hypertensive response.
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CHAPTER 3
HDAC INHIBITION ATTENUATES INFLAMMATORY, HYPERTROPHIC AND
HYPERTENSIVE RESPONSES IN SPONTANEOUSLY HYPERTENSIVE RATS*

*Reprinted with the kind permission of “Hypertension”
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INTRODUCTION
Essential hypertension is a condition associated with increased expression of proinflammatory cytokines (PICs) (Phillips and Kagiyama 2002; Ferrario and Strawn 2006). Studies
from our lab and others have shown that PICs lead to an increase in reactive oxygen species
(ROS), which up-regulates Nuclear Factor-kappaB (NFκB) activity, thus further increasing PIC
and ROS transcription and amplifying their subsequent actions (Sriramula, Haque et al. 2008;
Elks, Mariappan et al. 2009; Mariappan, Elks et al. 2009). Along with renin-angiotensin system
(RAS) components, PICs also activate hypertrophic mediators, which can result in cardiac
hypertrophy and altered cardiac remodeling and function (Tokuda, Kai et al. 2004; Kudo, Kai et
al. 2009).
There are many triggers of hypertensive-induced inflammation resulting in both
hypertrophic and hypertensive responses, many of which are through transcription factor NFκB
activation, ultimately resulting in alterations of gene transcription and perpetuation of the
hypertensive state (Gupta, Young et al. 2005; Sriramula, Haque et al. 2008). In order for
transcription factors such as NFκB to activate their target genes, DNA and chromatin remodeling
must occur. Post-translational modifications of histone cores through a tightly regulated
addition/removal of an acetyl tag on their N-terminal tails plays a major role in gene expression
modulation (de Ruijter, van Gennip et al. 2003). These additions/removals are accomplished by
several members of the histone acetyltransferase (HAT) and histone deacetylase (HDAC)
families, which either open or close DNA strands to the actions of transcription factors (Forsberg
and Bresnick 2001).
Normally, this balance is tightly controlled, but during conditions of stress and
inflammation, activation of PICs can result in increased HDAC activation and histone
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acetylation, correlating with an increase in NFκB activity and further increases in PIC
expression, including tumor necrosis factor-α (TNF) and the interleukins (ILs) (Keslacy, Tliba et
al. 2007; Kim, Rowe et al. 2007). Though HDACs would appear to repress inflammatory
responses through reduced gene expression, this view is too simplistic in regards to their nonhistone protein acetylation/deacetylation abilities, often times having quite opposite effects in
regards to the inflammatory response (Chen, Fischle et al. 2001; Chen, Weng et al. 2005; Kong,
Tannous et al. 2006; Bush and McKinsey 2009).
Recent evidence indicates that the various HDAC classes respond differently towards
inducing cardiac hypertrophy in non-hypertensive animal models (Zhang, McKinsey et al. 2002;
Kong, Tannous et al. 2006; Lee, Lin et al. 2007) and that global HDAC inhibition (HDACi) can
prevent these hypertrophic changes (Davis, Pillai et al. 2005). However, it is not known whether
HDACi protects against cardiac hypertrophy and hypertensive response by modulating PICs and
oxidative stress in spontaneously hypertensive (SHR) rats. A previous study used valproate, a
derivative of valproic acid (VPA), to study hypertension in SHR rats. Though they showed a
reduction in systolic blood pressure (Sasaki, Nakata et al. 1990), the treatment was only carried
out to 9 weeks of age, which is still 3 weeks too young to display the full systemic changes
associated with hypertension in this animal model, including cardiac hypertrophy and
inflammation. This study was established to assess the role of HDAC blockade on the
inflammatory response and its effect on the pathogenesis of hypertension. Therefore, we
hypothesize that chronic HDACi will attenuate the inflammatory and hypertensive responses
associated with the hypertensive state. To test this, we administered VPA, a fairly novel HDAC
inhibitor (Gottlicher, Minucci et al. 2001), especially Class I HDACs, as a long-term treatment in
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SHR rats, for assessment of inflammatory, hypertrophic and hypertensive changes associated
with essential hypertension.
MATERIALS AND METHODS
All the procedures in this study were approved by the Louisiana State University Institutional
Animal Care and Use Committee and were performed in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals.
Animals. Adult male SHR or WKY rats were used for this study. They were housed in
temperature- (23 ± 2°C) and light-controlled (lights on between 7 AM and 7 PM) animal quarters
and were provided with chow ad libitum. Vehicle (water) or valproic acid [VPA, 0.71% wt/vol
(Kook, Lepore et al. 2003), Sigma] dissolved in water were prepared and provided daily.
Another subset of animals (WKY and SHR; n=5 each) were administered hydralazine [HYD,
25mg/kg/day in drinking water (Gupta, Young et al. 2005), Sigma], a direct smooth muscle
relaxant and vasodilator, to determine the pressure-independent effect of VPA on cardiac
hypertrophy. The experimental procedures were approved by the Louisiana State University
Institutional Animal Care and Use Committee in accordance with the NIH Guide for the Care
and Use of Laboratory Animals.
Experimental Protocol. SHR (n=20) and WKY (n=20) rats underwent echocardiographic
assessment at the start and end of the treatment period. Rats received drug or vehicle treatment
for 20 weeks starting at 7 weeks of age. Rats were euthanized at 27 weeks of age. Wet heart and
lung weights were measured and analyzed against body weight. Blood and left ventricular tissue
(LV) was collected for molecular analysis.
Blood Pressure Measurement. A tail-cuff plethysmograph (CODA 6 Blood Pressure System,
Kent Scientific System, Torrington, CT) was used for blood pressure measurement at baseline,
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and weekly thereafter. Blood pressure was measured for four consecutive days for determination
of weekly average measures. The daily measurements were blindly analyzed for the most closely
associated five consecutive runs for use as that day’s average value.
Echocardiographic Assessment of LV Hypertrophy. Echocardiography was obtained at
baseline, and repeated at the end of the treatment period. Echocardiogram was performed as
described previously (Mariappan, Elks et al. 2009). Briefly, transthoracic echocardiography was
performed under isoflurane anesthesia, using a Toshiba Aplio SSH770 (Toshiba Medical, Tustin,
California) fitted with a PST 65A sector scanner (8 MHz probe) which generates twodimensional images at a frame rate ranging from 300-500 frames per second. Left ventricular
posterior wall thickness at end-systole and end-diastole (LVPWTs and LVPWTd, respectively)
was measured digitally on M-mode recordings and averaged from at least three cardiac cycles.
Assessment of LV Hypertrophy Through Fibrosis Staining. Paraffin sections (10μm) were
obtained from heart specimens as previously described (Sriramula, Haque et al. 2008) and
stained with picrosirius red for the detection of collagen. The percent area of fibrosis was
calculated using ImageJ software (NIH).
Detection of Total ROS and Superoxide (O2•−) in LV Heart Tissue. One of the most sensitive
and definitive methods of superoxide production is electron spin resonance (ESR). In this study,
we utilized an established technique for total ROS detection in tissue using ESR and spin traps
(Mariappan, Elks et al. 2009). Different spin probes were used for the ESR studies. 1-hydroxy3-methoxycarbonyl-2, 2, 5, 5-tetramethylpyrrolidine (CMH) was used to measure the O2•− levels.
All ESR measurements were performed using an EMX ESR eScan BenchTop spectrometer and
super-high quality factor (Q) microwave cavity (Bruker Company, Germany). Sample
Preparation for ESR studies: The dissected LV tissue from each animal was placed into a 24-
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well plate containing Kreb’s HEPES buffer (KHB) (20mM, pH 7.4). Tissue pieces were then
washed twice with the same buffer to remove any trace contamination. Samples were then
incubated at 37oC with specific spin probes for 30 minutes. Total tissue ROS production: Total
ROS was determined as previously described (Mariappan, Elks et al. 2009). Tissue pieces were
incubated at 37oC with CMH (200 μM) for 30 minutes. Aliquots of the incubated probe media
were then taken in 50 μl glass capillary tubes (Noxygen Science Transfer and Diagnostics,
Elzach, Germany) for determination of total ROS production, under the following ESR settings:
field sweep 50 G; microwave frequency 9.78 GHz; microwave power 20 mW; modulation
amplitude 2 G; conversion time 327 ms; time constant 655 ms; receiver gain 1 x 105. For
superoxide production, samples were pre-incubated at 37oC with PEG-SOD (50 U/ml) for 30
minutes, then CMH (200uM) for an additional 30 minutes. Aliquots of the incubated probe
media were taken in 50 μl glass capillary tubes for determination of total superoxide production.
Addition of PEG-SOD to CMH allowed competitive inhibition of the O2•−-CMH oxidation
reaction by the quenching of O2•− radicals. Since it is cell permeable, PEG-SOD can
competitively inhibit the CMH-O2•− interaction both intracellularly and extracellularly, thus
allowing accurate measurement of total tissue O2•- production. To determine actual total tissue
superoxide production, the values obtained from incubation with PEG-SOD and CMH were
subtracted from the values obtained from incubation with CMH only.
RNA Isolation and Real-Time RT-PCR. Total RNA was extracted from the LV using TRI
reagent (Invitrogen), and cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad) as
previously described (Guggilam, Haque et al. 2007; Sriramula, Haque et al. 2008). The mRNA
expression levels of ANP, Collagen IV, TNF, IL-1β, IL-6, the p50 subunit of NF-κB, gp91phox
and angiotensin II-Type 1 receptor (AT1R) were determined using previously published specific
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custom made primers (Guggilam, Haque et al. 2007; Sriramula, Haque et al. 2008; Agarwal,
Haque et al. 2009; Elks, Mariappan et al. 2009; Mariappan, Elks et al. 2009). GAPDH was used
as the housekeeping gene. Real-time RT-PCR (qRT-PCR) was performed in 384 well PCR plates
using Bio-Rad PCR Master Mix (The iTaq SYBR™ Green Supermix with ROX) and the ABI
Prism 7900 sequence detection system (Applied Biosystems). The PCR cycling conditions were
as follows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles (15 s at 95°C, 1 min, at
60°C). A dissociation step (15 s at 95°C, 15 s, at 60°C and 15 s at 95°C) was added to check the
melting temperature of the specific PCR product.
HDAC Activity Analysis by Colorimetric Assay. Nuclear extracts of LV tissue were obtained
with a Nuclear Extraction Kit (BioVision). Nuclear extract was then analyzed for HDAC activity
with a Colorimetric HDAC Activity Assay Kit (BioVision), both according to manufacturer’s
instructions. The plate was read by a Multiskan Spectrum system and values were determined as
O.D./μg protein in samples.
AT1R Protein Analysis by Western Blot. Protein was extracted from LV samples in ice-cold
buffer (10mM Tris-HCl, pH 7.4, 1mM EDTA, 1% Nonidet P-40, 0.1% sodium deoxycholate,
and 0.1% SDS) containing a protease inhibitor cocktail (Roche). The protein content in the
supernatant was determined using a detergent-compatible protein assay (Bio-Rad). Protein
samples (25μg) were resolved in 10% SDS-polyacrylamide gel.The protein expression of AT1R
in the heart was analyzed by Western blot as previously described (Sriramula, Haque et al. 2008)
with the use of anti-AT1R antibody (Santa Cruz). Bands were normalized to GAPDH.
Localization of TNF and IL-1β by Immunohistochemistry. Heart tissues were prepared as
previously described (Guggilam, Haque et al. 2007). The sections were treated with respective
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primary antibodies TNF (1:100 dilution, anti-goat) and IL-1β (1:50 dilution, anti-rabbit) (Santa
Cruz). Negative control sections were incubated with secondary antibody alone.
Localization of gp91phox by Immunofluorescence. For detection of gp91phox in LV heart
tissue, slides were incubated overnight at 4ºC with a 1:100 dilution of goat polyclonal antigp91phox (Santa Cruz) as previously described (Khaleduzzaman, Francis et al. 2007).
Electrophoretic Mobility Shift Assay (EMSA) for Assessment of NF-kB Activity. EMSA
was used to assess the activity of NF-kB (p65) in the left ventricle as previously described
(Agarwal, Haque et al. 2009).
Statistical Analysis of Data. All results are expressed as mean ± SEM. For statistical analysis of
the data, student’s t test, one-way ANOVA or repeated measures ANOVA followed by
Bonferroni’s post hoc test was performed using GraphPad Prism version 5.0 for Windows,
GraphPad Software, San Diego California, USA, to determine differences among groups.
Cardiac fibrosis measurements were compared by using nonparametric Kruskal-Wallis ANOVA
followed by Mann-Whitney U post hoc. A value of p<0.05 was considered significant.
RESULTS
VPA Treatment Attenuates the Blood Pressure Changes in SHR Rats. Blood pressure
recordings show that SHR+VPA maintained a lower blood pressure level from the prehypertensive to the more advanced hypertensive phases as compared to SHR controls (Figure
3.1). Following 10 weeks of treatment (started at 7 weeks of age), SHR control MAP continued
to rise while SHR+VPA rats plateaued at a lower pressure (163.1±2.32 vs. 127.5±2.35mmHg,
respectively, p<0.05). The MAP of SHR+VPA rose slightly throughout the course of the study,
becoming significantly elevated above WKY controls towards the end of the treatment period
(141.2±4.5 vs. 114.8±3.41, respectively, p<0.05), but still significantly lower than the MAP of
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SHR controls (141.2±4.5 vs. 173.2±3.47, respectively, p<0.05). Mean diastolic and systolic
pressures followed the same pattern as the MAP (data not shown), indicating that VPA
attenuated all phases of blood pressure in SHR rats. Furthermore, VPA did not have any adverse
effects on the health of the animals used in this study.

Figure 3.1. Effects of VPA and HYD treatment on MAP. VPA and HYD attenuated the
increase in MAP seen in untreated SHR rats. n=5-8 in each group, *p<0.05 vs WKY, #p<0.05
vs SHR.
Another set of animals (n=5 for each SHR and WKY) were treated with HYD, a direct
smooth muscle relaxant and vasodilator, to compare their effects against treatment with VPA
(Figure 3.1). SHR+HYD saw a decrease similar to SHR+VPA in MAP as compared to SHR
(142.57±4.906 vs. 173.2±3.47). WKY+HYD had no change in MAP. Mean diastolic and systolic
followed the same pattern as the MAP in HYD treated rats (data not shown), indicating that
HYD similarly attenuated all phases of increased blood pressure seen in SHR rats.
VPA Attenuates Cardiac Hypertrophy in SHR Rats. Echocardiographic assessment showed
that SHR controls had significantly more concentric hypertrophy of the left ventricular posterior
wall (LVPWT) during diastole and systole (Figure 3.2A) (2.48±0.11 and 3.43±0.2mm,
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respectively) when compared to WKY controls (1.73±0.02 and 2.32±0.06, respectively).
However, SHR+VPA (1.85±0.03, 2.52±0.04mm) rats displayed no change in ventricular
thickness as compared to WKY and WKY+VPA (1.75±0.06, 2.28±0.07mm) rats, indicating that
VPA had a beneficial effect on preventing the increased LVPWTd/s that is typically observed in
SHR rats.
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Figure 3.2. Effects of VPA treatment on cardiac hypertrophy. VPA attenuated ventricular
wall thickness as assessed by echocardiography (A) during both diastole and systole. VPA
also attenuated the HW/BW (indicating reduction in cardiac hypertrophy) and LW/BW
(indicating reduction in lung edema due to reduced cardiac function) ratio in SHR rats (B).
SHR rats had increased levels of ANP and Collagen IV mRNA expression which were
reduced with VPA treatment (C). Graphs expressed as fold change versus WKY rats. VPA
reduced cardiac fibrosis versus SHR rats as indicated by picrosirius red staining collagen
versus total area (D). Stained slides are representative of typical results for each group
(n=3/group). n=7-8 in each group, *p<0.05 vs WKY, #p<0.05 vs SHR.
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Heart weight (HW)/body weight

A

(BW) and lung weight (LW)/BW ratios are
often used to show phenotypic changes due
to hypertension such as increased heart
mass due to hypertrophy (HW/BW) and
increased edema of the lungs (LW/BW)

B

due to cardiac dysfunction and increased
systemic circulatory resistance. Treatment
with VPA or HYD alone did not have any
effects on BW (Figure 3.3A). SHR+VPA
normalized both HW/BW and LW/BW
indices versus SHR control rats (0.0032
and 0.0048 vs. 0.0039 and 0.0062,
respectively, p<0.05) as compared to WKY

Figure 3.3. Effects on VPA and HYD
treatment on BW and cardiac hypertrophy.
There were no BW differences across SHR and
WKY rats or between treatment groups. VPA
attenuated the HW/BW (indicating reduction in
cardiac hypertrophy) ratio, whereas HYD had
minimal effect in reducing cardiac hypertrophy
in SHR rats. n=7-8 in each group, *p<0.05 vs
WKY, #p<0.05 vs SHR.

(0.0029 and 0.0038), reinforcing that VPA
reduces cardiac hypertrophy and dysfunction (Figure 3.2B). However, the HW/BW ratio
assessed for SHR+HYD did not improve cardiac hypertrophy (Figure 3.3B) as compared to SHR
controls (0.0036 vs. 0.0039), indicating that improvements in cardiac hypertrophy due to VPA
treatment were not pressure dependent.
VPA Reduces Hypertrophic Response Elements in the LV Tissue of SHR Rats. To further
demonstrate the effects of VPA on hypertrophy, RT-PCR analysis was undertaken on
hypertrophic response genes in the LV. Compared to WKY, untreated SHR rats had elevated
levels of collagen IV and atrial natriuretic peptide (ANP) - two markers of LV remodeling
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associated with cardiac hypertrophy (Figure 3.2C), as well AT1R. SHR+VPA reduced these
levels to that of normotensive WKY controls (p<0.05), indicating HDACi has a positive effect
on reducing molecular markers of cardiomyocyte and interstitial growth normally attributed to
systemic hypertension. Furthermore, SHR+VPA had reduced % fibrosis staining (Figure 3.2D)
as compared to SHR rats (3.395±0.07 vs 4.713±0.32), signifying a reduction in total fibrosis
within the heart following HDACi. The mRNA expression of AT1R was significantly increased
within the LV of SHR rats versus that of normotensive WKY controls (2.7±0.5 fold vs WKY)
(Figure 3.4B), which was fully attenuated in SHR+VPA rats (2.7±0.5 vs. 0.9±0.1 fold vs WKY,
respectively) and reconfirmed by western blot of the LV tissues (Figure 3.4A). HYD had no
effect on the mRNA expression of either ANP or AT1R (Figure 3.5A, B), demonstrating the
effect that HDACi has on controlling these locally activated hypertrophic mediators in the LV of
SHR rats.

Figure 3.4. Effect of VPA on AT1R mRNA and protein expression. Untreated SHR rats
showed higher mRNA (B) and protein expression (A) levels of the AT1R in the LV when
compared to WKY controls. SHR+VPA attenuated this increase. Western blot protein
expression bands were normalized to GAPDH. n=7-8 in each group, *p<0.05 vs SHR.
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VPA Reduces HDAC Activity in the LV
of Treated Groups. To assess the
effectiveness of VPA on HDAC activity
in LV tissue, a colorimetric assay kit was
used to analyze differences between the
VPA treated and untreated groups (Figure
3.6A). Global HDAC activity was reduced
in untreated WKY versus untreated SHR
rats (17.87±1.06 vs. 22.19±0.57 O.D./mg
protein sample, respectively, p<0.05).
Figure 3.5. Effects of HYD treatment on
hypertrophic markers. SHR rats had increased
levels of ANP (A) and AT1-R (B) mRNA
expression compared to WKY controls. These
levels remained unchanged following HYD
treatment. n=5-8 in each group, *p<0.05 vs SHR,
#p<0.05 vs SHR+HYD.

Furthermore, WKY+VPA and SHR+VPA
groups both exhibited a lower HDAC
activity level (not significant and p<0.05,
respectively) as compared to their own

strain controls. Conversely, SHR and WKY rats treated with HYD did not have a decrease in
HDAC activity when compared with their respective controls (data not shown).
VPA Normalizes Inflammatory Response in the LV Tissue of SHR Rats. Immunohistochemistry revealed that SHR controls had increased protein expression of TNF and IL-1β in
the LV as compared to WKY controls. This protein expression was reduced in SHR+VPA rats
(Figure 3.7A). RT-PCR similarly indicated that SHR controls had increased expression of TNF,
IL-1β, IL-6 (Figure 3.7B) mRNA and NFκB p65 (Figure 3.6B, C) activity and mRNA in LV
tissue when compared to WKY controls. This increase was attenuated in SHR+VPA rats, while
WKY+VPA exhibited no change. Furthermore, HYD had no effect on the PIC mRNA
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expression of TNF or IL-1β (data not shown). These combined results indicate that VPA
treatment reduces and normalizes the inflammatory response observed in SHR rats.
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Figure 3.6. Effects of VPA on HDAC activity as assessed through a colorimetric
detection assay and NFκB (p65) activity and expression via EMSA and real-time RTPCR, respectively, in the LV. HDAC activity was elevated in both WKY and SHR rats
versus WKY+VPA and SHR+VPA rats (A). Untreated SHR HDAC activity was elevated
versus untreated WKY rats. Untreated SHR rats had an increased activity (as determined by
EMSA) and mRNA expression of NF-κB which was attenuated in SHR+VPA (B, C). n=7-8
in each group, *p<0.05 vs SHR.
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VPA Reduces ROS and gp91phox in the LV of SHR Rats. As inflammation during
hypertensive response is associated with an increase in oxidative stress, both total ROS as
assessed by EPR (Figure 3.8A) and the expression of gp91phox (Figure 3.8B, 6C) were
examined in the LV. Untreated SHR rats experienced a significant increase in ROS when
compared to WKY rats (0.54±0.05 vs. 0.22±0.03mM/mg protein/min). SHR+VPA normalized
this ROS increase (0.54±0.05 vs. 0.21±0.03mM/mg protein/min). Furthermore, gp91phox, the
major catalytic subunit of NADPH oxidase and a ROS contributor, was increased in untreated
SHR rats versus WKY controls. This was subsequently reduced in SHR+VPA (3.39 vs. 1.56 fold
change/WKY), but not SHR+HYD (data not shown). The reduction in protein expression was
confirmed by immunofluorescence of the LV tissue. These results indicate that treatment of
SHR rats with VPA had beneficial effects in reducing oxidative stress in the LV tissue.
DISCUSSION
The major findings in this study are as follows: 1) HDACs played an important role in
hypertensive drive by modulating inflammatory and oxidative stress actions and contributed to
hypertrophic and hypertensive responses in SHR rats, 2) HDACi attenuated MAP in SHR rats, 3)
HDACi also attenuated LVPWT and HW/BW ratio in SHR rats, demonstrating that HDACi
reduces cardiac hypertrophy, possibly in part through modulation of ANP, Collagen IV and
AT1R expression, 4) untreated SHR rats had an increase in inflammatory markers, including
TNF and NFκB, as well as an increase in ROS and gp91phox expression, which were decreased
through long-term HDACi using VPA, and 5) HDACi reduced AT1R expression, thereby
limiting the role that angiotensin II (Ang II) plays in mediating hypertension. These findings
suggest that long-term treatment with VPA reduces hypertension-induced PICs, thereby
attenuating hypertrophic and hypertensive responses in SHR rats.
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Figure 3.7. Effects of VPA treatment on TNF and IL-1β protein and mRNA expression.
SHR rats had notably increased protein staining of TNF and IL-1β in the LV when compared
to WKY rats as shown through immunohistochemical staining (A). This staining increase
was markedly reduced in SHR+VPA. Images shown represent results observed in
preparations from 4 to 6 rats. Untreated SHR rats had increased levels of PIC expression
compared to WKY rats (B). SHR+VPA reduced this increased expression in the LV tissue.
n=7-8 in each group, *p<0.05 vs SHR.
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Figure 3.8. Effects of VPA treatment on tROS and
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increased mRNA (B) and protein (C) expression of
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the LV versus WKY rats. This was attenuated in
SHR+VPA. Immunofluorescence of LV
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gp91phox in SHR rats versus SHR+VPA. n=7-8 in
each group, *p<0.05 vs SHR.

Aung, Schroder et al. 2006;
Brogdon, Xu et al. 2007; Ito,
Charron et al. 2007; Kim, Rowe et
al. 2007; Halili, Andrews et al.
2009). In this study, we also
observed an elevated HDAC activity

which was accompanied by increased PIC and oxidative stress gene expression in the hearts of
SHR rats.
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Cardiac hypertrophy is a well described consequence of systemic hypertension. Studies
have shown the role of HDACi on controlling cardiac growth and remodeling (Antos, McKinsey
et al. 2003). However, little is known about the holistic role of HDACi on hypertrophy during
hypertensive response. As evidence indicates (Zhang, McKinsey et al. 2002; Antos, McKinsey et
al. 2003; Davis, Pillai et al. 2005; Kee, Sohn et al. 2006; Kong, Tannous et al. 2006),
pathological cardiac hypertrophy and function rely upon the balanced abundance of α- and βmyosin heavy chain (MHC) protein throughout the heart. During the progression of cardiac
hypertrophy, the adult isoform of MHC (α-MHC) undergoes a stressed-trigger switch to the fetal
isoform (β-MHC), contributing to cardiac hypertrophy. HDACi blunts MHC isoform switching,
therefore preserving ventricular function (Kong, Tannous et al. 2006; Lee, Lin et al. 2007; Bush
and McKinsey 2009). These results are contradictory to earlier experiments showing that class II
HDACs block pro-growth genes through interaction with transcription factor myocyte enhancer
factor-2 (MEF2) (McKinsey, Zhang et al. 2002). More recently though, research has indicated
that the pro-hypertrophic class I HDACs, when activated, are more potent and take priority over
the anti-hypertrophic class II HDACs (Antos, McKinsey et al. 2003), thus explaining how global
HDACi can attenuate cardiac hypertrophy in various animal models (Kee, Sohn et al. 2006;
Kong, Tannous et al. 2006). From these changes, it has been suggested that within the
hypertrophied heart, hypertrophic stress signals cause the phosphorylation of HDACs bound to
MEF2, causing their disassociation into the cytoplasm. Since these HDACs are not bound to the
chromatin structure, their inhibition would have no overt effect on MEF2 transcription,
indicating that HDACi has no direct effect on the depression of MEF2 controlled prohypertrophic genes and signifying that another mechanism must be in place (Kong, Tannous et
al. 2006).
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HDACi using Trichostatin A, an inhibitor of Class I and II HDACs, either induced
(Kuwahara, Saito et al. 2001) or blunted (Antos, McKinsey et al. 2003) agonist-induced
expression of ANP, a hypertrophic growth factor, in cultured neonatal myocytes. The present
study also demonstrated that HDACi in SHR rats showed a significant reduction in ANP,
suggesting that in SHR rats, ANP possibly plays an important role in attenuating cardiac
hypertrophy, and that HDACi silences/blunts this signaling mechanism. Moreover, collagen IV,
an indicator of cardiac remodeling, especially within the failing heart (Grimm, Huber et al.
2001), was increased in SHR rats, but not SHR+VPA rats. Finally, AT1R, an important
component of the RAS which, when acted upon by Ang II in the LV, causes cardiac hypertrophy
(Makino, Sugano et al. 1997), has been shown to be attenuated with VPA treatment (Kee, Sohn
et al. 2006; Lu and Yang 2009), but the mechanism involved has not been fully investigated. The
present study showed significantly reduced AT1R expression in SHR+VPA rats versus SHR
controls, indicating that a possible hypertrophic mechanism intimately involves AT1R activation.
There are several well known modulators of pressure-independent cardiac hypertrophy
including Ang II and sympathetic neurohormones (Kang, Ma et al. 2009). Recently, it was also
shown that Ang II-induced cardiac hypertrophy can be prevented using HDACi (Kee, Sohn et al.
2006). To determine if the current study’s effects on cardiac hypertrophy were pressureindependent or -dependent of HDACi, we looked at the effect of HYD on blood pressure and
cardiac hypertrophy, as well as on ANP and AT1R expression. HYD reduced MAP in SHR rats
similar to VPA; however, cardiac hypertrophy was unaffected, including hypertrophic mediators
ANP and AT1R. This indicates a possible pressure-independent mechanism regarding VPA’s
effect on cardiac hypertrophy. These results are in agreement with a recent study where NFκB
inhibition reduces cardiac hypertrophy in a pressure-independent manner (Gupta, Young et al.
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2005). This may offer another mechanism whereby HDACi reduces cardiac hypertrophy, for
results herein show a decrease in NFκB activity and expression following VPA treatment.
Therefore, from these results, not only was cardiac hypertrophy reduced through long-term VPA
treatment, but several possible mechanisms that induce cardiac remodeling were also attenuated.
We and others have recently demonstrated that hypertensive drive is partially controlled
through the over-expression of PICs, especially TNF, along with downstream alterations in
NFκB, ROS and RAS components, as regulated through AT1R activation (Wilcox and Welch
2001; Sriramula, Haque et al. 2008; Elks, Mariappan et al. 2009; Mariappan, Elks et al. 2009).
This study demonstrates that chronic HDACi attenuates PIC response in SHR+VPA rats.
Moreover, VPA reduces the presence of ROS and AT1R, two components implicated in the
inflammatory response observed in hypertension. HDACi has been increasingly identified as a
possible therapeutic approach towards many inflammatory conditions, including cardiovascular
diseases (Gottlicher, Minucci et al. 2001; Adcock 2007; Bush and McKinsey 2009; Halili,
Andrews et al. 2009). Though this mechanism has not yet been entirely delineated, it is
suggested that the use of a HDACi, such as VPA, blocks HDAC actions on protein function
outside of its normal action on altering transcription (Chen, Weng et al. 2005; Bode, Schroder et
al. 2007), as subsets of these families possess the ability to act on non-histone proteins, further
complicating their roles in gene modulation (Walkinshaw, Tahmasebi et al. 2008). A recent
study showed that HDACi can deactivate Akt, a potential mediator of cardiac hypertrophy and
oxidative stress, via dephosphorylation by HDAC-protein phosphatase 1 complexes (Chen,
Weng et al. 2005). However, other studies have shown that specific sets of Toll-like receptorinducible genes are targeted by HDACi in macrophages and dendritic cells, and that one of these
is through the NFκB pathway (Aung, Schroder et al. 2006; Brogdon, Xu et al. 2007), which
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concurs with the present study. It underscores the role of HDACi on PIC activation of NFκB,
preventing a further, cyclically driven up-regulation of PICs, including TNF, IL-1β and IL-6.
The effect of inflammation on ROS in hypertension has been previously demonstrated
(Paravicini and Touyz 2006; Elks, Mariappan et al. 2009). A number of pro-inflammatory
mediators of this increased ROS have been identified, including TNF and IL-6, which, as
demonstrated here, are attenuated with HDACi, confirming the roles of HDACs on inflammatory
and oxidative stress responses on hypertension in SHR rats. Though the signaling pathway is not
entirely clear on how HDACi attenuates ROS in SHR rats, either directly or indirectly through its
blockade of PICs and the NFκB pathway, we postulate that by blocking PIC activation, with its
subsequent down-regulation of NFκB activity and gp91phox expression, ROS is inhibited.
The interaction between the RAS, PICs and ROS has also been demonstrated by work in
our lab (Sriramula, Haque et al. 2008) and others (Brasier, Li et al. 1996; Sasamura, Nakazato et
al. 1997; Arenas, Xu et al. 2004). Presently we show that untreated SHR rats have increased
AT1R expression, an important component of the pro-hypertensive portion of the RAS. HDACi
through VPA treatment attenuated this increase concomitant with that of PICs. The
pathophysiological mechanism of hypertension intimately involves the action of Ang II,
including vasoconstriction, increased aldosterone secretion, increased sympathetic nerve activity,
tissue remodeling and increased sodium and water intake, all of which are mediated through
AT1Rs that are distributed throughout most organ systems, including the liver, brain, kidney,
heart and blood vessels (Allen, Zhuo et al. 2000). Reports indicate that Ang II is controlled by,
and controls, HDAC-induced changes in gene and protein response (Kee, Sohn et al. 2006; Lu
and Yang 2009). Here we show a possible new mechanism involving the regulation of Ang II
responses as directed through the AT1R. HDACi reduces AT1R gene expression and receptor
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density, thereby ameliorating the actions of Ang II. This alteration in AT1R expression could be
either through direct HDACi effects on the receptor’s production and function, or through the
effects of HDACi on inflammatory gene response during hypertension. This mechanism must be
further investigated in order to determine the full effect of HDACi in attenuating hypertension.
In conclusion, the present study’s results show that long-term HDACi through VPA
attenuated MAP and cardiac hypertrophy, possibly through modulation of ANP, Collagen IV and
AT1R. HDAC inhibition also attenuated the increased inflammatory response, including TNF
and NFκB, as well as the increase in ROS and gp91phox. These findings suggest that HDACi
with VPA reduced inflammation, ROS, and AT1R, thereby attenuating hypertension and its
secondary consequences in SHR rats.
PERSPECTIVES
We chose to use VPA due to its current use in clinical settings as an anti-seizure and
bipolar drug, demonstrating its availability to patients. In our study, VPA was administered longterm without any adverse effects towards the treated animal groups. This outlines the importance
of the continuous drug administration necessary for the successful treatment of hypertension and
its consequences, including cardiac hypertrophy, systemic inflammation and end organ damage
due to ROS. While we cannot rule out the effects of VPA on blood pressure from its GABAergic
actions or non-histone protein interactions, we feel confident that this study provides sufficient
evidence that the use of HDACi can reduce not only blood pressure, but cardiac hypertrophy and
the inflammatory state associated with hypertension. The specific mechanisms involved in
HDACi must be studied more closely. However, as the quest to find new therapeutic strategies in
hypertensive control is ever pressing, this could present a possible new approach in future
treatment options.

79

REFERENCES
Adcock, I. M. (2007). "HDAC inhibitors as anti-inflammatory agents." Br J Pharmacol 150(7):
829-831.
Agarwal, D., M. Haque, et al. (2009). "Role of Proinflammatory Cytokines and Redox
Homeostasis in Exercise-Induced Delayed Progression of Hypertension in Spontaneously
Hypertensive Rats." Hypertension 54: 1393-1400.
Allen, A. M., J. Zhuo, et al. (2000). "Localization and function of angiotensin AT1 receptors."
Am J Hypertens 13(1 Pt 2): 31S-38S.
Antos, C. L., T. A. McKinsey, et al. (2003). "Dose-dependent blockade to cardiomyocyte
hypertrophy by histone deacetylase inhibitors." J Biol Chem 278(31): 28930-28937.
Arenas, I. A., Y. Xu, et al. (2004). "Angiotensin II-induced MMP-2 release from endothelial
cells is mediated by TNF-alpha." Am J Physiol Cell Physiol 286(4): C779-784.
Aung, H. T., K. Schroder, et al. (2006). "LPS regulates proinflammatory gene expression in
macrophages by altering histone deacetylase expression." FASEB J 20(9): 1315-1327.
Bode, K. A., K. Schroder, et al. (2007). "Histone deacetylase inhibitors decrease Toll-like
receptor-mediated activation of proinflammatory gene expression by impairing
transcription factor recruitment." Immunology 122(4): 596-606.
Brasier, A. R., J. Li, et al. (1996). "Tumor necrosis factor activates angiotensinogen gene
expression by the Rel A transactivator." Hypertension 27(4): 1009-1017.
Brogdon, J. L., Y. Xu, et al. (2007). "Histone deacetylase activities are required for innate
immune cell control of Th1 but not Th2 effector cell function." Blood 109(3): 1123-1130.
Bush, E. W. and T. A. McKinsey (2009). "Targeting histone deacetylases for heart failure."
Expert Opin Ther Targets 13: 767-784.
Chen, C. S., S. C. Weng, et al. (2005). "Histone acetylation-independent effect of histone
deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1
complexes." J Biol Chem 280(46): 38879-38887.
Chen, L., W. Fischle, et al. (2001). "Duration of nuclear NF-kappaB action regulated by
reversible acetylation." Science 293(5535): 1653-1657.
Davis, F. J., J. B. Pillai, et al. (2005). "Concurrent opposite effects of trichostatin A, an inhibitor
of histone deacetylases, on expression of alpha-MHC and cardiac tubulins: implication
for gain in cardiac muscle contractility." Am J Physiol Heart Circ Physiol 288(3): H14771490.

80

de Ruijter, A. J., A. H. van Gennip, et al. (2003). "Histone deacetylases (HDACs):
characterization of the classical HDAC family." Biochem J 370(Pt 3): 737-749.
Elks, C. M., N. Mariappan, et al. (2009). "Chronic NF-{kappa}B blockade reduces cytosolic and
mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR." Am
J Physiol Renal Physiol 296(2): F298-305.
Ferrario, C. M. and W. B. Strawn (2006). "Role of the renin-angiotensin-aldosterone system and
proinflammatory mediators in cardiovascular disease." Am J Cardiol 98(1): 121-128.
Forsberg, E. C. and E. H. Bresnick (2001). "Histone acetylation beyond promoters: long-range
acetylation patterns in the chromatin world." Bioessays 23(9): 820-830.
Gottlicher, M., S. Minucci, et al. (2001). "Valproic acid defines a novel class of HDAC
inhibitors inducing differentiation of transformed cells." EMBO J 20(24): 6969-6978.
Grimm, D., M. Huber, et al. (2001). "Extracellular matrix proteins in cardiac fibroblasts derived
from rat hearts with chronic pressure overload: effects of beta-receptor blockade." J Mol
Cell Cardiol 33(3): 487-501.
Guggilam, A., M. Haque, et al. (2007). "TNF-alpha blockade decreases oxidative stress in the
paraventricular nucleus and attenuates sympathoexcitation in heart failure rats." Am J
Physiol Heart Circ Physiol 293(1): H599-609.
Gupta, S., D. Young, et al. (2005). "Inhibition of NF-kappaB induces regression of cardiac
hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats."
Am J Physiol Heart Circ Physiol 289(1): H20-29.
Halili, M. A., M. R. Andrews, et al. (2009). "Histone deacetylase inhibitors in inflammatory
disease." Curr Top Med Chem 9(3): 309-319.
Ito, K., C. E. Charron, et al. (2007). "Impact of protein acetylation in inflammatory lung
diseases." Pharmacol Ther 116(2): 249-265.
Kang, Y. M., Y. Ma, et al. (2009). "Brain nuclear factor-kappa B activation contributes to
neurohumoral excitation in angiotensin II-induced hypertension." Cardiovasc Res 82(3):
503-512.
Kee, H. J., I. S. Sohn, et al. (2006). "Inhibition of histone deacetylation blocks cardiac
hypertrophy induced by angiotensin II infusion and aortic banding." Circulation 113(1):
51-59.
Keslacy, S., O. Tliba, et al. (2007). "Inhibition of tumor necrosis factor-alpha-inducible
inflammatory genes by interferon-gamma is associated with altered nuclear factorkappaB transactivation and enhanced histone deacetylase activity." Mol Pharmacol 71(2):
609-618.
81

Khaleduzzaman, M., J. Francis, et al. (2007). "Infection of cardiomyocytes and induction of left
ventricle dysfunction by neurovirulent polytropic murine retrovirus." J Virol 81(22):
12307-12315.
Kim, H. J., M. Rowe, et al. (2007). "Histone deacetylase inhibitors exhibit anti-inflammatory and
neuroprotective effects in a rat permanent ischemic model of stroke: multiple
mechanisms of action." J Pharmacol Exp Ther 321(3): 892-901.
Kong, Y., P. Tannous, et al. (2006). "Suppression of class I and II histone deacetylases blunts
pressure-overload cardiac hypertrophy." Circulation 113(22): 2579-2588.
Kook, H., J. J. Lepore, et al. (2003). "Cardiac hypertrophy and histone deacetylase-dependent
transcriptional repression mediated by the atypical homeodomain protein Hop." J Clin
Invest 112(6): 863-871.
Kudo, H., H. Kai, et al. (2009). "Exaggerated blood pressure variability superimposed on
hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated
chronic inflammation." Hypertension 54(4): 832-838.
Kuwahara, K., Y. Saito, et al. (2001). "The neuron-restrictive silencer element-neuron-restrictive
silencer factor system regulates basal and endothelin 1-inducible atrial natriuretic peptide
gene expression in ventricular myocytes." Mol Cell Biol 21(6): 2085-2097.
Lee, T. M., M. S. Lin, et al. (2007). "Inhibition of histone deacetylase on ventricular remodeling
in infarcted rats." Am J Physiol Heart Circ Physiol 293(2): H968-977.
Lu, Y. and S. Yang (2009). "Angiotensin II induces cardiomyocyte hypertrophy probably
through histone deacetylases." Tohoku J Exp Med 219(1): 17-23.
Makino, N., M. Sugano, et al. (1997). "Molecular mechanism of angiotensin II type I and type II
receptors in cardiac hypertrophy of spontaneously hypertensive rats." Hypertension
30(4): 796-802.
Mariappan, N., C. M. Elks, et al. (2009). "TNF-induced mitochondrial damage: a link between
mitochondrial complex I activity and left ventricular dysfunction." Free Radic Biol Med
46(4): 462-470.
McKinsey, T. A., C. L. Zhang, et al. (2002). "MEF2: a calcium-dependent regulator of cell
division, differentiation and death." Trends Biochem Sci 27(1): 40-47.
Paravicini, T. M. and R. M. Touyz (2006). "Redox signaling in hypertension." Cardiovasc Res
71(2): 247-258.
Phillips, M. I. and S. Kagiyama (2002). "Angiotensin II as a pro-inflammatory mediator." Curr
Opin Investig Drugs 3(4): 569-577.
82

Sasaki, S., T. Nakata, et al. (1990). "Chronic central GABAergic stimulation attenuates
hypothalamic hyperactivity and development of spontaneous hypertension in rats." J
Cardiovasc Pharmacol 15(5): 706-713.
Sasamura, H., Y. Nakazato, et al. (1997). "Regulation of vascular type 1 angiotensin receptors by
cytokines." Hypertension 30(1 Pt 1): 35-41.
Sriramula, S., M. Haque, et al. (2008). "Involvement of tumor necrosis factor-alpha in
angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy."
Hypertension 51(5): 1345-1351.
Tokuda, K., H. Kai, et al. (2004). "Pressure-independent effects of angiotensin II on hypertensive
myocardial fibrosis." Hypertension 43(2): 499-503.
Wade, P. A. (2001). "Transcriptional control at regulatory checkpoints by histone deacetylases:
molecular connections between cancer and chromatin." Hum Mol Genet 10(7): 693-698.
Walkinshaw, D. R., S. Tahmasebi, et al. (2008). "Histone deacetylases as transducers and targets
of nuclear signaling." J Cell Biochem 104(5): 1541-1552.
Wilcox, C. S. and W. J. Welch (2001). "Oxidative stress: cause or consequence of hypertension."
Exp Biol Med (Maywood) 226(7): 619-620.
Zhang, C. L., T. A. McKinsey, et al. (2002). "Class II histone deacetylases act as signalresponsive repressors of cardiac hypertrophy." Cell 110(4): 479-488.

83

CHAPTER 4
CENTRAL TUMOR NECROSIS FACTOR-α BLOCKADE REVERSES ANGIOTENSIN
II-INDUCED ALTERATIONS IN RENIN-ANGIOTENSIN SYSTEM COMPONENTS
AND ATTENUATES HYPERTENSION

84

INTRODUCTION
It is well known that the renin-angiotensin system (RAS) plays a major role in blood
pressure regulation and the hypertensive condition. While the pro-hypertensive components of
the RAS have been extensively investigated, the recent identification of an anti-hypertensive set
of RAS components has complicated the manner by which the fully activated RAS functions in
physiological and pathophysiological states. Angiotensin II (Ang II), the effector peptide of the
pro-hypertensive axis of the RAS that also includes angiotensin converting enzyme (ACE) and
the Ang II-Type 1 receptor (AT1R), exerts diverse physiological actions in both the peripheral
and central neural systems. The anti-hypertensive counterbalance to these mediators includes
ACE2, and the AT2 and Mas receptors. Importantly, all these essential components of the RAS,
including renin and angiotensinogen, as well as various cardiovascular-modulatory
aminopeptidases, are synthesized within the brain, suggesting the existence of a comprehensive
intrinsic brain RAS (Bader and Ganten 2002; Veerasingham and Raizada 2003; Sakai and
Sigmund 2005; Xu, Sriramula et al. 2011). Recent evidence suggests that dysregulation of the
individual brain RAS arms may play a critical role in the development and maintenance of
hypertension. Ang II, acting through the AT1R, plays a prominent role in the central regulation
of blood pressure by activating the sympathetic nervous system, regulating fluid and salt balance
and the secretion of aldosterone, amongst other actions (Veerasingham and Raizada 2003).
Furthermore, the pressor response of chronic low-dose Ang II infusion in animals has been
shown, at least in part, to be sympathetically driven (Bruner and Fink 1986; Gorbea-Oppliger
and Fink 1994). Previous studies suggest that systemically delivered Ang II likely acts upon the
circumventricular organs, where the blood brain barrier is weak or absent, and subsequently
activates hypothalamic and brain stem sites such as the paraventricular nucleus (PVN) and
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ventrolateral medulla, contributing to sympathoexcitation and hypertensive response (Simpson
1981; Fink, Bruner et al. 1987; Collister and Hendel 2003).
Experimental evidence indicates that the hypothalamic PVN is an important center for
integrating Ang II-induced neural outflow signals for the pressor response and sympathetic
vasomotor tone (Martin, Segura et al. 1991; Zhu, Gao et al. 2004). Recent findings from our lab
and others suggest that the RAS, in addition to inducing neurohumoral excitation, also increases
the production of proinflammatory cytokines (PICs), such as tumor necrosis factor-alpha (TNF),
in brain cardiovascular regulatory centers, and has been shown to contribute to the neurogenic
component of hypertension, both through direct actions and through modulating reactive oxygen
species (ROS) signaling pathways (Kang, Ma et al. 2009; Shi, Diez-Freire et al. 2010). A chronic
increase in peripheral Ang II levels is proposed to initiate a cascade of signaling events involving
PICs and ROS in brain cardioregulatory sites raising sympathetic activity, hypertension and end
organ damage. These observations, coupled with the emerging role of PICs and the little known
role of the anti-hypertensive axis of the RAS in hypertension led us to hypothesize that the
central effects of Ang II are, at least in part, mediated by the activation of PICs, especially TNF.
The resultant of these actions are the differentially dysregulated RAS arms within cardiovascular
relevant brain regions, including the PVN, ultimately enhancing the neurogenic hypertensive
response. Presently, we investigate this hypothesis by examining central TNF inhibition via
intracerebroventricular (ICV) etanercept (ETN) infusion, a soluble TNF receptor fusion protein,
on pro- and anti-hypertensive RAS components in the PVN in Ang II-induced hypertension.
MATERIALS AND METHODS
Animals. Male Sprague-Dawley rats (8-10 weeks old) were used in this study. Animals were
housed in a temperature-controlled room (25 ± 1oC) and maintained on a 12:12 hour light:dark
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cycle with free access to food and water. All animal and experimental procedures were reviewed
and approved by the Institutional Animal Care and Use Committee (IACUC) at Louisiana State
University in compliance with NIH guidelines.
Experimental Protocol. The rats were implanted with radio-telemetry transmitters to measure
blood pressure, and subjected to ICV infusion of etanercept (10μg/kg/day) or artificial
cerebrospinal fluid (aCSF) (Alzet, model 1004; 0.11μl/hr), with and without subcutaneous
infusion of Ang II (200 ng/kg/min) for 4 weeks. Osmotic minipumps (Alzet, model 2004;
0.25μl/hr) were filled with Ang II dissolved in 0.9% saline or saline alone, and were implanted
subcutaneously in the retroscapular area. The rats were divided into 4 groups: 1) Control group saline minipumps + ICV aCSF, 2) ETN group - saline minipumps + ICV ETN, 3) Ang II group Ang II minipump + ICV aCSF, and 4) Ang II+ETN group - Ang II minipump + ICV etanercept.
At the end of the study, rats were euthanized the brain was removed for further analysis.
Blood Pressure Measurement. Blood pressure was measured continuously in conscious rats
implanted with radio-telemetry transmitters (Model TA11PA-C40, Data Sciences International,
St. Paul, MN). Rats were anesthetized with a ketamine (90 mg/kg) and xylazine (10 mg/kg)
mixture (i.p.) and placed dorsally on a heated surgical table. An incision was made on the ventral
surface of the left leg, and the femoral artery and vein were exposed and bluntly dissected apart.
The femoral artery was ligated distally, and a small clamp was used to temporarily interrupt the
blood flow. The catheter tip was introduced through a small incision in the femoral artery,
advanced 6 cm into the abdominal aorta such that the tip was distal to the origin of the renal
arteries, and secured into place. The body of the transmitter was placed into the abdominal cavity
and secured to the abdominal wall. The abdominal musculature was sutured and the skin layer
was closed following implantation. Rats received benzathine penicillin (30000 U, i.m.) and
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buprenorphine (0.1 mg/kg, s.c.) immediately following surgery and 12 h postoperatively and
allowed to recover for seven days.
ICV Cannula Implantation. Following the transmitter recovery period, the rats were implanted
with ICV cannula for infusion of ETN or aCSF (Francis, Weiss et al. 2003). The rats were
anaesthetized and the head was positioned in a Kopf stereotaxic apparatus. An ICV cannula was
implanted into the right lateral cerebroventricle (1.3 mm caudal to bregma, 1.5 mm lateral to the
midline, and 3.5 mm ventral to the dura) according to Paxinos and Watson, and fixed to the
cranium using small screws and dental cement. A 4-week osmotic minipump was implanted
subcutaneously and connected to the infusion cannula via the catheter tube to deliver ETN or
aCSF into the brain.
Real Time RT-PCR. PVN punches were made from frozen brain sections using a Stoelting
brain punch (Stoelting). Total RNA was isolated from PVN tissue using RNeasy plus micro kit
(Qiagen) and cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad). Real Time
PCR amplification reactions were performed with iQ SYBR Green Super mix with ROX (BioRad) using the ABI Prism 7900 Real time PCR machine (Applied Biosystems). List of primers
used was provided in Table 4.1. Data were normalized to GAPDH expression by the ∆∆CT
comparative method.
Immunohistochemical Analysis. Rats (n=5 in each group) were transcardially perfused with
200 ml of ice-cold PBS (7.4 pH; 0.1M) followed immediately by 200 ml of 4%
paraformaldehyde in PBS. The brains were removed, post-fixed in 4% paraformaldehyde
solution for 2 hours, and transferred to a phosphate buffer containing 20% sucrose (pH 7.4) and
stored overnight. For immunostaining, 10 µm coronal sections from paraffin embedded brains
were collected on slides. First the sections were incubated with 0.3% H2O2 in methanol for 10
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minutes. For antigen retrieval, citrate buffer with microwave heating technique is used. Then the
sections were incubated with 1.5% goat or rabbit serum in PBS containing 0.3% Triton X100 for
30 minutes. The sections were incubated with primary antibodies overnight at 4°C followed by
incubation with biotinylated goat-anti rabbit or rabbit-anti goat secondary antibodies for 60
minutes, and stained with Vectastain ABC kit (Vector Laboratories) according to the
manufacturer’s instructions. Each step was followed by washing the sections with PBS
containing 0.3% Triton X100. Sections incubated without primary antibody were used as
negative controls.
Statistical Analysis. All results are expressed as mean±SEM. For statistical analysis of the data,
student’s t test, one-way ANOVA or repeated measures ANOVA followed by Bonferroni’s post
hoc test was performed using GraphPad Prism version 5.0 for Windows (GraphPad Software,
San Diego California, USA) to determine differences among groups. A value of p<0.05 was
considered statistically.
RESULTS
Effect of Ang II Infusion on the Mean Arterial Pressure. To assess the effect of central TNF
blockade on the Ang II-induced hypertensive pressure response, mean arterial pressure (MAP)
was measured using a radio-telemetry system (Figure 4.1A). After 28 days, chronic Ang II
infusion significantly increased the MAP in rats when compared with control rats (164.9±5.03
mmHg vs 107.7±8.03 mmHg, respectively; p<0.05). In contrast, ICV treatment with etanercept
attenuated the Ang II-induced increase in MAP (126.4±21.2 mmHg vs 164.9±5.03 mmHg,
respectively; p<0.05), while ETN treatment alone had no effect on MAP (103.6±3.47 mmHg).
To evaluate Ang II-induced changes on cardiac hypertrophy in these rats, the hearts were
harvested and weighed at the end of experimental period. The ratio of heart/body weight
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(HW/BW) was calculated as an indicator of cardiac growth. Chronic Ang II infusion lead to
increased cardiac mass when compared to controls (4.04±0.2 vs 3.16±0.1 mg/g, respectively;
p<0.05), as indicated by the increased HW/BW ratio (Figure 4.1B). ICV treatment with ETN
inhibited Ang II-mediated cardiac growth (reduced to 3.15±0.1 mg/g; p<0.05). This data
suggests a role for TNF in the brain on Ang II-induced blood pressure regulation and cardiac
hypertrophy in the hypertension state.
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Figure 4.1. Effects of central TNF blockade mean arterial blood pressure (MAP) and
cardiac hypertrophy. MAP was increased after 28-day chronic Ang II infusion, this was
attenuated in Ang II+ETN rats (A). HW/BW ratio as assessed upon sacrifice shows an
increase in cardiac mass 28-day Ang II treatments versus controls (B). Etanercept reversed
this increase in cardiac mass. n=9-10 per group, *p<0.05 vs Control, #p<0.05 vs Ang II.
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Effect of Ang II Infusion on the Expression of PICs in the PVN. To determine the effect of
Ang II on the production of PICs and chemokines, the mRNA expression of TNF, IL-6, IL-1β,
and the chemokine MCP-1 were measured in the PVN by real time RT-PCR (Figure 4.2). Ang II
infusion induced an increase in the gene expression of the PICs TNF, IL-6 and IL-1β, and the
chemokine MCP-1, in the PVN, when compared to saline and saline+ETN control rats. These
PICs were attenuated in the PVN of Ang II-infused rats treated ICV with ETN, demonstrating
that chronic Ang II infusion increases the pro-inflammatory response within the PVN through
TNF in Ang II-induced hypertension.

IL-6

TNF
3

*

3
2

#

1

mRNA Expression
(fold increase)

mRNA Expression
(fold increase)

4

*
2
#
1

0

0

MCP-1

IL-1

2
1
0

4

*
#

mRNA Expression
(fold increase)

mRNA Expression
(fold increase)

4
3

Control
ETN
Ang II
Ang II+ETN

*
3

#

2

Control
ETN
Ang II
Ang II+ETN

1
0

Figure 4.2. Effects of central TNF blockade PIC and chemokine expression in the PVN.
Chronic Ang II infusion increased the expression of TNF, IL-1β, IL-6 and the chemokine
MCP-1 in the PVN. This increase in PIC expression was attenuated in Ang II+ETN rats.
n=9-10 per group, *p<0.05 vs Control, #p<0.05 vs Ang II.
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Figure 4.3. Effects of central TNF blockade pro-hypertensive RAS component
expression in the PVN. Chronic, 28-day Ang II infusion increased the mRNA expression of
AT1R and ACE in the PVN, which was attenuated in Ang II+ETN rats (3A).
Immunohistochemical staining against the AT1R in the PVN followed a similar pattern of
increase in Ang II-treated rats, but reduced following ICV etanercept administration (3B).
n=9-10 per group, *p<0.05 vs Control, #p<0.05 vs Ang II.
Effect of Ang II Infusion on the Expression of RAS Components in the PVN. Both Ang II
and TNF have been shown to modulate RAS component expression. To determine the manner by
which Ang II infusion alters the expression of the pro- and anti-hypertensive components of the
RAS in the PVN, we examined the mRNA expression levels of ACE, ACE2, AT1R, AT2R, and
the Mas receptor by real time RT-PCR, and the protein expression of the AT1R using
immunohistochemistry. The gene expression of the pro-hypertensive RAS components (AT1R
and ACE) in the PVN were significantly increased in Ang II-infused rats when compared with
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control rats; whereas in Ang II-infused rats treated ICV with ETN, these components were
reduced (Figure 4.3A). Immunohistochemistry against AT1R protein expression in the PVN
showed a similar pattern of increase
in Ang II-infused rats, but a
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Figure 4.4. Effects of central TNF blockade antihypertensive RAS component expression in the
PVN. Chronic, 28-day Ang II infusion decreased the
mRNA expression of ACE2, AT2R and the Mas
receptor in the PVN. This decrease was reversed in
Ang II+ETN rats. n=9-10 per group, *p<0.05 vs
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not only the recovery, but the overshoot observed in the ACE2 response by also not inhibiting
the machinery (possibly including a ROS mechanism) responsible for modulating ACE2. This
dysregulation is possibly through a PIC/TNF-mediated mechanism, and thereby perpetuating the
Ang II-driven hypertensive response.
Effect of Ang II Infusion on the Expression of gp91phox and nNOS. Both Ang II and TNF
have been shown to act through oxidative stress mediated pathways, especially within the PVN,
in inducing elevated sympathetic outflow and a progressive hypertensive response. Therefore,
we analyzed the PVN mRNA expression of gp91phox, the catalytic subunit of NADPH, and
neuronal Nitric Oxide Synthase (nNOS; an indirect indicator of sympathoexcitation). Ang II
infusion significantly increased the gp91phox subunit, and decreased nNOS mRNA expression,
in Ang II infused rats; these changes were reversed in Ang II-infused rats treated with ETN
(Figure 4.5). This data suggests that in Ang II-induced hypertension, oxidative stress (indicated
by increased gp91phox) and sympathoexcitation (indicated by a decreased nNOS) increase, and
that this is potentially through a TNF-driven mechanism.
DISCUSSION
The major findings in this study are as follows: 1) Chronic Ang II infusion increased
mean arterial blood pressure and cardiac hypertrophy; 2) within the PVN, chronic Ang II
infusion increased PICs such as TNF and IL-1β, as well as gp91phox and decreased nNOS; 3)
Ang II infusion also led to an elevation in pro-hypertensive RAS component expression (ACE
and AT1R) and a decrease in anti-hypertensive RAS component expression (ACE2, AT2R and
Mas) within the PVN; 4) Ang II-infused rats treated ICV with etanercept, a soluble TNF receptor
mimetic, prevented these changes, including attenuating MAP and PICs, and reversing the
expression alterations observed between the pro- and anti-hypertensive RAS arms. These
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findings demonstrate that the changes observed in Ang II-induced hypertension are regulated, at
least in part, through the central actions of TNF and potentially via the dysregulation of
components of the RAS within the hypothalamic PVN.

A

gp91phox

nNOS
2.0

*

4
3

#

2
1
0

mRNA Expression
(fold increase)

mRNA Expression
(fold increase)

5

#

1.5

Control
ETN
Ang II
Ang II+ETN

1.0

*
0.5
0.0

Control

B

Ang II

Ang II+ETN

gp91phox

Figure 4.5. Effects of central TNF blockade on oxidative stress marker gp91phox and
nNOS expression in the PVN. Ang II-infused rats demonstrated an increase in the mRNA
expression of the NADPH oxidase catalytic subunit, gp91phox, while that of nNOS was
decreased in the PVN (5A). These alterations were reversed in etanercept-treated rats.
Similarly, immunofluorescence against gp91phox showed an increased neuronal expression
in Ang II-infused rats, which was decreased in Ang II+ETN rats (5B). n=9-10 per group,
*p<0.05 vs Control, #p<0.05 vs Ang II.
Recent evidence suggests that hypertension is an inflammatory condition where various
PICs such as TNF, IL-6 and IL-1β, both centrally and peripherally, have been shown to play an
important role in the pathogenesis of hypertension (Chae, Lee et al. 2001; Veerasingham and
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Raizada 2003; Sun, Li et al. 2004; Sriramula, Haque et al. 2008; Lu, Chen et al. 2009; Shi, DiezFreire et al. 2010). A recent study from our lab demonstrated that chronic peripheral Ang II
infusion results in increased production of PICs within the PVN (Kang, Ma et al. 2009).
Blockade of TNF by etanercept has been shown to prevent renal damage in a genetic
hypertensive rat model, as well as lower blood pressure in rats with Ang II- and salt-induced
hypertension, suggesting a role for TNF in blood pressure regulation and renal injury (Muller,
Shagdarsuren et al. 2002; Elmarakby, Quigley et al. 2006). Another study also showed that mice
treated with etanercept had an attenuated hypertension and a blunted increase in superoxide
production in response to Ang II (Guzik, Hoch et al. 2007). Etanercept is a soluble recombinant
fusion protein the inhibits TNF by posing as a TNF receptor decoy and acting through
competitive inhibition of TNF and an overall reduction in free TNF to act on endogenous
receptors (Goffe and Cather 2003). Our present observations complement these findings and
show that ICV administration of etanercept into the brain protects rats against Ang II-dependent
cardiac hypertrophy and hypertension.
Ang II can act as a potent proinflammatory agent and stimulate the production of
chemokines such as MCP-1, and PICs, such as TNF, IL-6 and IL-1β in the brain (Shi, DiezFreire et al. 2010). TNF is commonly considered as one of the initiators of the pro-inflammatory
cascade, which can induce production of other cytokines and chemokines (Zhang, Hein et al.
2006; Zhang, Xu et al. 2006). A recent study demonstrated that Ang II-induced hypertension
involves activation of microglia and increased expression of PICs within the PVN (Shi, DiezFreire et al. 2010). In our study, TNF blockade with etanercept decreased the expression not only
of TNF, but of other cytokines such as IL-6, IL-1β, and chemokine MCP-1 within the PVN,
supporting the hypothesis that PIC are involved in the Ang II-induced hypertensive response.
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Excessive ROS production in brain cardio-regulatory centers such as the PVN can
contribute to the neurogenic component of the hypertensive response by enhancing sympathetic
activity and outflow (Paravicini and Touyz 2006). It has been shown that NADPH oxidase is the
primary source of Ang II-induced ROS in neurons (Paravicini and Touyz 2006) and that
treatment with the cell permeable superoxide dismutase (SOD) mimetic Tempol inhibits Ang IImediated superoxide production and hypertension (Nishiyama, Fukui et al. 2001). Furthermore,
TNF can induce activation of NADPH oxidase leading to enhanced oxidative stress and
decreasing the bioavailability of NO (Zhang, Xu et al. 2006). Moreover, in the present study,
nNOS was decreased in the PVN of Ang II-treated rats, but restored following ICV etanercept
administration. Neuronal NOS is an inverse indirect indicator of sympathoexcitation, in that a
decrease in nNOS correlates with an increase in sympathetic outflow. Therefore, a reduction in
beneficial NO not only decreases with the reduction in nNOS expression and activity, but along
with the rapid interconversion of NO to peroxynitrite (ONOO-) with the ever increasing
production of NADPH oxidase-derived superoxide. These factors combined can lead to an
increased PIC response, sympathoexcitation and a continued propagation of neurgenic
hypertension. The present study provides further support for these observations by showing that
central TNF blockade with etanercept reduced the expression of gp91phox (the catalytic subunit
of NADPH oxidase), restored nNOS, and ultimately decreased the changes associated with the
hypertensive state.
In many animal models of hypertension, the expression of the AT1R is upregulated in
central cardiovascular regulatory centers, including the hypothalamic PVN (Veerasingham and
Raizada 2003). In the brain, the AT1R mediates the central effects of Ang II, including
vasopressin release, water and salt intake and balance, and increased sympathetic drive, all of
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which contribute to the development of hypertension (Paul, Poyan Mehr et al. 2006; von Bohlen
und Halbach and Albrecht 2006). Both in vitro and in vivo studies have demonstrated the
existence of a cross-talk between Ang II and TNF (Sasamura, Nakazato et al. 1997; Arenas, Xu
et al. 2004), and we have also shown that attenuation of Ang II-induced hypertension in TNF
knockout mice involves a decreased expression of AT1R (Sriramula, Haque et al. 2008).
Presently, we show that chronic Ang II infusion results in an increase in PVN ACE and AT1R,
both which were reduced following ICV etanercept infusion. Recently, the discovery of an
alternate set of components of the RAS which may act as a counterbalance to the actions of the
ACE/Ang II/AT1R pathway added complexity to the understanding of RAS regulation,
especially within the brain (Xu, Sriramula et al. 2011). These components, termed antihypertensive due to their cardio-protective effects, along with all the components of the prohypertensive RAS axis, are known to be expressed throughout the various central cardioregulatory regions, including the PVN. In various experimental hypertensive models, these
components (ACE2, AT2R, Ang (1-7) and the Mas receptor) are shown to be downregulated,
while the pro-hypertensive components are increased. This dysregulation may be the lynch pin
trigger towards developing hypertension, but its management is poorly understood. In the present
study, ICV treatment with etanercept resulted in reduction of Ang II-induced pro-hypertensive
RAS component expression, including ACE and AT1R upregulation in the PVN, as well as the
restoration of the anti-hypertensive RAS components ACE2, AT2R and the Mas receptor. As
mentioned previously, ACE2 can increase during the normal RAS response, but following the
eventual increase in TNF, it decreases ACE2 as well as the other anti-hypertensive RAS
components. Thus, the TNF blockade possibly allows for not only the recovery, but the
overshoot observed in the ACE2 response by not inhibiting the machinery responsible for
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moderating and modulating ACE2. However, these same signaling mechanisms seem to have
little to no effect on the AT2R and Mas receptor gene expression increases. This/these
mechanism(s) must be studied closely to delineate these observed differences. These results
suggest that this RAS dysregulation and perpetuation of the hypertensive state may be the result
of a pro-inflammatory response through the actions of TNF, but further studies are necessary to
completely understand this mechanism.
In summary, chronic Ang II infusion resulted in cardiac hypertrophy and hypertension,
and within the PVN, an increased PIC and gp91phox expression, and decreased expression of
nNOS. Perhaps more importantly, Ang II-infused rats had an increased expression of the
injurious pro-hypertensive RAS components ACE and AT1R, and a decreased expression of the
protective anti-hypertensive RAS components ACE2, AT2R and the Mas receptor. Central
blockade of TNF with etanercept resulted in attenuation of hypertension, cardiac hypertrophy
and PIC expression, decreased oxidative stress, as well as a restored the balance between the
protective and deleterious arms of the RAS, within the hypothalamic PVN. The beneficial effects
of central TNF blockade in Ang II-induced hypertensive responses appears to be mediated by the
returned balance of the central RAS components, especially within the PVN. It is important to
note, however, that due to the administration of etanercept ICV, the TNF inhibitory effects may
have impacted additional cardio-regulatory regions in the brain and elicited a similar response as
in the PVN, but in light of its central integrative function versus the other regions, the PVN was
of utmost concern. These other regions should also be investigated in future studies, as well as a
closer look at the specific pathway between Ang II, TNF and the differential regulation of the
RAS arms in the Ang II hypertension-induced animal model. Our findings provide further
evidence and insight for the involvement of the RAS within the PVN and its interaction and
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mediation through TNF in the neurogenic component of hypertension. Further exploration of
these system interactions within the brain may be beneficial towards the development of novel
hypertensive therapeutics.
REFERENCES
Arenas, I. A., Y. Xu, et al. (2004). "Angiotensin II-induced MMP-2 release from endothelial
cells is mediated by TNF-alpha." Am J Physiol Cell Physiol 286(4): C779-784.
Bader, M. and D. Ganten (2002). "It's renin in the brain: transgenic animals elucidate the brain
renin angiotensin system." Circ Res 90(1): 8-10.
Bruner, C. A. and G. D. Fink (1986). "Neurohumoral contributions to chronic angiotensininduced hypertension." Am J Physiol 250(1 Pt 2): H52-61.
Chae, C. U., R. T. Lee, et al. (2001). "Blood pressure and inflammation in apparently healthy
men." Hypertension 38(3): 399-403.
Collister, J. P. and M. D. Hendel (2003). "Subfornical organ lesion attenuates chronic
hypotensive effects of losartan in salt-replete rats." J Renin Angiotensin Aldosterone Syst
4(4): 207-212.
Elmarakby, A. A., J. E. Quigley, et al. (2006). "Tumor necrosis factor alpha blockade increases
renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive
hypertension." Hypertension 47(3): 557-562.
Fink, G. D., C. A. Bruner, et al. (1987). "Area postrema is critical for angiotensin-induced
hypertension in rats." Hypertension 9(4): 355-361.
Francis, J., R. M. Weiss, et al. (2003). "Central mineralocorticoid receptor blockade decreases
plasma TNF-alpha after coronary artery ligation in rats." Am J Physiol Regul Integr
Comp Physiol 284(2): R328-335.
Goffe, B. and J. C. Cather (2003). "Etanercept: An overview." J Am Acad Dermatol 49(2 Suppl):
S105-111.
Gorbea-Oppliger, V. J. and G. D. Fink (1994). "Clonidine reverses the slowly developing
hypertension produced by low doses of angiotensin II." Hypertension 23(6 Pt 2): 844847.
Guzik, T. J., N. E. Hoch, et al. (2007). "Role of the T cell in the genesis of angiotensin II induced
hypertension and vascular dysfunction." J Exp Med 204(10): 2449-2460.

100

Kang, Y. M., Y. Ma, et al. (2009). "Brain nuclear factor-kappa B activation contributes to
neurohumoral excitation in angiotensin II-induced hypertension." Cardiovasc Res 82(3):
503-512.
Lu, Y., J. Chen, et al. (2009). "Angiotensin II receptor 1 involved in the central pressor response
induced by interleukin-1 beta in the paraventricular nucleus." Neurol Res 31(4): 420-424.
Martin, D. S., T. Segura, et al. (1991). "Cardiovascular responses to bicuculline in the
paraventricular nucleus of the rat." Hypertension 18(1): 48-55.
Muller, D. N., E. Shagdarsuren, et al. (2002). "Immunosuppressive treatment protects against
angiotensin II-induced renal damage." Am J Pathol 161(5): 1679-1693.
Nishiyama, A., T. Fukui, et al. (2001). "Systemic and Regional Hemodynamic Responses to
Tempol in Angiotensin II-Infused Hypertensive Rats." Hypertension 37(1): 77-83.
Paravicini, T. M. and R. M. Touyz (2006). "Redox signaling in hypertension." Cardiovasc Res
71(2): 247-258.
Paul, M., A. Poyan Mehr, et al. (2006). "Physiology of local renin-angiotensin systems." Physiol
Rev 86(3): 747-803.
Sakai, K. and C. D. Sigmund (2005). "Molecular evidence of tissue renin-angiotensin systems: a
focus on the brain." Curr Hypertens Rep 7(2): 135-140.
Sasamura, H., Y. Nakazato, et al. (1997). "Regulation of vascular type 1 angiotensin receptors by
cytokines." Hypertension 30(1 Pt 1): 35-41.
Shi, P., C. Diez-Freire, et al. (2010). "Brain Microglial Cytokines in Neurogenic Hypertension."
Hypertension.
Simpson, J. B. (1981). "The circumventricular organs and the central actions of angiotensin."
Neuroendocrinology 32(4): 248-256.
Sriramula, S., M. Haque, et al. (2008). "Involvement of tumor necrosis factor-alpha in
angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy."
Hypertension 51(5): 1345-1351.
Sun, C., H. Li, et al. (2004). "Macrophage migration inhibitory factor: an intracellular inhibitor
of angiotensin II-induced increases in neuronal activity." J Neurosci 24(44): 9944-9952.
Veerasingham, S. J. and M. K. Raizada (2003). "Brain renin-angiotensin system dysfunction in
hypertension: recent advances and perspectives." Br J Pharmacol 139(2): 191-202.
von Bohlen und Halbach, O. and D. Albrecht (2006). "The CNS renin-angiotensin system." Cell
Tissue Res 326(2): 599-616.

101

Xu, P., S. Sriramula, et al. (2011). "ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of
good." Am J Physiol Regul Integr Comp Physiol 300(4): R804-817.
Zhang, C., T. W. Hein, et al. (2006). "Activation of JNK and xanthine oxidase by TNF-alpha
impairs nitric oxide-mediated dilation of coronary arterioles." J Mol Cell Cardiol 40(2):
247-257.
Zhang, C., X. Xu, et al. (2006). "TNF-alpha contributes to endothelial dysfunction in
ischemia/reperfusion injury." Arterioscler Thromb Vasc Biol 26(3): 475-480.
Zhu, G. Q., L. Gao, et al. (2004). "ANG II in the paraventricular nucleus potentiates the cardiac
sympathetic afferent reflex in rats with heart failure." J Appl Physiol 97(5): 1746-1754.

102

CHAPTER 5
NUCLEAR FACTOR-kappaB BLOCKADE IN THE PARAVENTRICULAR NUCLEUS
MODULATES RENIN-ANGIOTENSIN SYSTEM COMPONENTS AND ATTENUATES
HYPERTENSION
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INTRODUCTION
Hypertension is a condition closely associated with the renin-angiotensin system (RAS)
and increased expression of proinflammatory cytokines (PICs) and reactive oxygen species, in
both systemic and local hypertensive responses (Chae, Lee et al. 2001; Zimmerman, Lazartigues
et al. 2002; Davisson 2003; Gao, Wang et al. 2005; Ferrario and Strawn 2006; Granger 2006;
Kang, Ma et al. 2009). Studies from our laboratory and others have shown that in hypertension,
angiotensin II (AngII), PICs and ROS can increase the activity of the transcription factor Nuclear
Factor-kappaB (NFκB), which in turn, can further increase PIC and ROS expression in a positive
feed-forward manner (Allen, Zhuo et al. 2000; van den Berg, Haenen et al. 2001; Zhang, Wei et
al. 2003; Bubici, Papa et al. 2006; Tian, Moore et al. 2007; Kang, Ma et al. 2009; Cardinale,
Sriramula et al. 2010).
Within the brain, multiple cardio-regulatory regions exhibit a local RAS, including the
hypothalamic paraventricular nucleus (PVN), which can synthesize and release both pro- and
anti-hypertensive RAS component peptides (Davisson 2003; Xia and Lazartigues 2008). The
PVN is recognized as a central integration site for the coordination of autonomic and
neuroendocrine responses that regulate thirst, salt appetite and sympathetic outflow (Davisson,
Oliverio et al. 2000; de Wardener 2001; Sriramula, Haque et al. 2008). AngII is a large peptide
that cannot cross the blood-brain barrier (BBB). Therefore, it exerts its roles by acting on the
circumventricular organs (CVOs), an area where the BBB is either weak or absent (Simpson
1981; Ganong 2000). Signals from these CVOs subsequently activate neurons within the various
cardio-regulatory centers of the brainstem and hypothalamus, including the PVN (Ganong 2000),
which can respond by locally producing components of the RAS and via sympathetic signals to
the periphery (Kang, Ma et al. 2009).
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Recent findings from our laboratory and others have shown that, with hypertension, PICs
are increased in discrete brain sites, such as the PVN, and that signals from both the systemic and
local RASs increase PICs and oxidative stress (Kang, Ma et al. 2009; Shi, Raizada et al.). Within
the PVN, the RAS, PICs and ROS have been linked to increased sympathoexcitation and
perpetuation of the hypertensive state (Sun, Li et al. 2004; Lu, Chen et al. 2009). Based upon the
preceding evidence, we hypothesized that bilateral PVN blockade of NFκB would attenuate
these observed regional changes which propagate the AngII-induced hypertensive response,
including increases in PICs and ROS. To test this hypothesis, we blocked NFκB within the PVN
using two different approaches: bilateral PVN NFκB decoy oligodeoxynucleotide infusion, or
bilateral PVN microinjection of an Adenoviral vector containing a serine mutated InhibitoykappaB (IκB) (AdIκB). These inhibition techniques block two separate locations in the NFκB
transcription activation pathway, prior to entering the nucleus (AdIκB) and following nuclear
translocation (NFκB decoy). Our results demonstrate that NFκB is integral to perpetuating the
hypertensive state through transcriptional activation of the local RAS, PIC and ROS actions
within the PVN, as well as acting as a tipping point modulator in the balance between the prohypertensive and the anti-hypertensive arms of the RAS. This data shows the important role that
PVN specific NFκB plays in the neurogenic control of hypertension through RAS modulation.
MATERIALS AND METHODS
Animals. Male Sprague-Dawley rats (12 weeks old, 250-350grams, n=153) were used in this
study. Animals were housed in a temperature- (25 ± 1oC) and light-controlled (12:12 hour
light:dark cycle) room with free access to water and normal rat chow (0.4% salt). All animal
procedures were reviewed and approved by the Institutional Animal Care and Use Committee
(IACUC) at Louisiana State University in accordance with NIH guidelines.
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Experimental Protocol. Rats were anaesthetized and implanted with radio-telemetry
transmitters. Following a 7-day recovery, bilateral cannulae were placed into the PVN. Fourteenday osmotic minipumps (Alzet, model 2002) with an infusion rate of 0.5µl/h were filled with
AngII (Bachem, 200ng/kg/min) dissolved in 0.9% saline, or saline alone, and implanted
subcutaneously in the retroscapular area. Simultaneously, osmotic minipumps (infusion rate of
0.11µl/h; Alzet, model 1004) were filled with NFκB decoy or control scrambled decoy
oligodeoxynucleotide (2ng/kg/min; Sigma), dissolved in aCSF, implanted subcutaneously in the
retroscapular area and connected to the cannula. The NFκB decoy concentration was determined
from a previous pilot study in rats using three different doses, 200pg/kg/min, 2ng/kg/min and
200ng/kg/min. The 2ng/kg/min dose was found to be optimal, while the highest dose caused
increased mortality and the lowest dose did not produce complete NFκB inhibition as measured
using an NFκB (p65) activity assay. Rats were divided into 4 groups: 1) No treatment (Controls;
n=11); 2) Saline minipump + bilateral PVN NFkB decoy (Saline+NFκB decoy; n=8); 3) AngII
minipump + bilateral PVN scrambled decoy (AngII+Scramble decoy; n=8); and 4) AngII
minipump + bilateral PVN NFκB decoy (AngII+NFκB decoy; n=20). Another group of rats were
also implanted with radio-telemetry transmitters and allowed a 7-day recovery. These rats were
injected (2x1010 pfu/ml, 100nL) bilaterally intra-PVN with an Adenoviral vector (Ad) containing
IκB serine mutated at the S23A/S36A positions (AdIκB), or a control Ad with an empty cassette
region (AdEmpty; both adenoviruses obtained from Gene Transfer Vector Core, University of
Iowa, Carver College of Medicine) using a 1µl Hamilton syringe, as previously described (Feng,
Yue et al. 2008). Also in this group of rats, 14-day osmotic minipumps (Alzet, model 2002;
0.5µl/h) were filled with AngII dissolved in 0.9% saline or saline alone and implanted
subcutaneously into the retroscapular area. These rats were also divided into 4 groups: 1) No
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treatment (Controls; n=10); 2) Saline minipump + bilateral PVN AdIκB (Saline+AdIκB; n=9); 3)
AngII minipump + bilateral PVN AdEmpty (AngII+AdEmpty; n=8); and 4) AngII minipump +
bilateral PVN AdIκB (AngII+AdIκB; n=21). A final group of rats were treated with AngII alone
(n=15) and used for western blot, immunohistochemical and electron paramagnetic resonance
(EPR) analysis. All rats were euthanized using a high ketamine+xylazine dose after 14 days of
blood pressure recordings and brain tissue was collected for mRNA and protein analysis (1.8μg
mRNA and 8-12μg protein extracted/side). All rats that received treatment unilaterally into the
PVN or had malfunctioning pumps (based upon post-mortem analysis) were excluded from the
final analysis (success rate: bilateral cannulation ~ 78%; bilateral microinjection ~ 65%). Chow
salt (Na+) content did not appear to have any effect on pressure response. A p<0.05 was
considered significant.
Blood Pressure Measurement. Blood pressure was measured continuously in conscious rats
implanted with radio-telemetry transmitters (Model TA11PA-C40, Data Sciences International,
St. Paul, MN). Rats were anesthetized with a ketamine (90 mg/kg) and xylazine (10 mg/kg)
mixture (i.p.) and placed dorsally on a heated surgical table. An incision was made on the ventral
surface of the left leg, and the femoral artery and vein were exposed and bluntly dissected apart.
The femoral artery was ligated distally, and a small clamp was used to temporarily interrupt the
blood flow. The catheter tip was introduced through a small incision in the femoral artery,
advanced 6 cm into the abdominal aorta such that the tip was distal to the origin of the renal
arteries, and secured into place. The body of the transmitter was placed in to the abdominal
cavity and sutured to the abdominal wall. The abdominal musculature was sutured and the skin
layer was closed. Rats received benzathine penicillin (30000 U, i.m.) and buprenorphine (0.1
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mg/kg, s.c.) immediately following surgery and 12 h postoperatively. The rats were allowed 7day surgical recovery.
Bilateral Cannula Implantation or Intra-PVN Injections. Rats to receive NFκB decoy or
scrambled oligodeoxynucleotide decoy were anesthetized with ketamine (90 mg/kg) and
xylazine (10 mg/kg) mixture (i.p.). The rats were placed in a stereotaxic instrument (Kopf
instruments; Tujunga, CA) and the skull was exposed through an incision on the midline of the
scalp. After bregma was identified, the coordinates for the PVN were determined from the
Paxinos and Watson (2007) rat atlas, at 1.8 mm posterior and 7.9 mm ventral to the zero level.
Rats were implanted with custom designed bilateral cannulae (Plastics One; Roanoke, VA) and
subsequently attached to osmotic mimipumps via sterile vinyl tubing. For adenovirus
microinjections, we followed the same surgical procedure except that rats were injected
bilaterally intra-PVN with AdIκB or AdEmpty virus using a 1μl Hamilton syringe with a custom
made needle/tip and injector plunger that advances flush with the needle tip (Hamilton Company
USA) at ±0.4 mm lateral to the bregma. ICV cannulated rats were examined for cannula
placement during cryostat slicing with crystal violet staining prior to PVN punching and
immunohistochemical slicing (bilateral cannulation ~ 78%; n=22). Microinjection locations were
also determined via crystal violet staining prior to PVN punching and immunohistochemical
slicing (bilateral microinjection ~ 65%; n=24). At this point, animals identified as receiving
unilateral or no treatments were removed from the final analysis. Animals not able to be
examined via staining methods were assessed based on pressure recordings, as the unilaterallytreated rats had a distinctive blood pressure range from the AngII+Scramble decoy and
AngII+AdEmpty and the AngII+ NFκB decoy and AngII+ AdIκB treatment groups.
Detection of Total ROS, Superoxide and Peroxynitrite in PVN Tissue. One of the most
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sensitive and definitive methods of total ROS, superoxide and peroxynitrite production is
electron spin resonance (EPR). In this study, we utilized an established technique for ROS
detection in tissue using EPR and spin traps as previously described (Cardinale, Sriramula et al.
2010; Guggilam, Cardinale et al. 2011).
RNA Isolation and Real-Time RT-PCR . Total RNA was extracted from the PVN using TRI
reagent (Invitrogen), and cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad) as
previously described (Guggilam, Haque et al. 2007; Sriramula, Haque et al. 2008). The mRNA
expression levels of TNF, IL-1β, IL-6, MCP-1, AT1R, ACE, ACE2, the Mas receptor and nNOS
were determined using previously published specific custom made primers (Guggilam, Haque et
al. 2007; Sriramula, Haque et al. 2008; Agarwal, Haque et al. 2009; Elks, Mariappan et al. 2009;
Mariappan, Elks et al. 2009). GAPDH was used as the housekeeping gene. Real-time RT-PCR
(qRT-PCR) was performed in 384 well PCR plates using Bio-Rad PCR Master Mix (The iTaq
SYBR™ Green Supermix with ROX) and the ABI Prism 7900 sequence detection system
(Applied Biosystems). The PCR cycling conditions were as follows: 50°C for 2 min, 95°C for 10
min, followed by 40 cycles (15 s at 95°C, 1 min, at 60°C). Finally, a dissociation step (15 s at
95°C, 15 s, at 60°C and 15 s at 95°C) was added to check the melting temperature of the specific
PCR product.
Western Blot. Western blot analysis was performed according to standard protocols. The PVN
tissue was homogenized with RIPA lysis buffer. Equal amounts of protein (5µg) were SDSPAGE separated on 10% wt/vol gels, transferred to PVDF membrane (Immobilon-P, Millipore)
and blocked with 1% BSA in TBS-T at room temperature for 60 min. The membranes were
subjected to immunoblot analyses with anti-AT1 (Abcam), anti-MasR (Santa Cruz) and antiGAPDH (Santa Cruz) antibodies (1:200 dilution). Immunodetection was accomplished with a
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horse radish anti-rabbit or anti-goat secondary antibody (1:2000 dilution) using an enhanced
chemiluminescence kit (Amersham) as previously described (Sriramula, Haque et al. 2008). The
data were quantified using ImageJ software and were normalized to GAPDH expression.
Immunohistochemical Analysis. Rats (n=4 in each group) were transcardially perfused with
200ml of ice-cold PBS (7.4 pH; 0.1M) followed immediately by 200 ml of 4% paraformaldehyde
in PBS. The brains were removed, postfixed in 4% paraformaldehyde solution for 2 hours, and
transferred to a phosphate buffer containing 20% sucrose (pH 7.4) and stored overnight. For
immunostaining, 10µm coronal sections from paraffin embedded brains were collected on slides.
First the sections were incubated with 0.3% H2O2 in methanol for 10 minutes. For antigen
retrieval, citrate buffer with microwave heating technique is used. Then the sections were
incubated with 1.5% goat or rabbit serum in PBS containing 0.3% Triton X100 for 30 minutes.
The sections were incubated with primary antibodies (TNF, 1:100 dilution, anti-goat; Santa
Cruz; nNOS, 1:100 dilution, anti-goat; Santa Cruz) overnight at 4°C followed by incubation with
biotinylated goat-anti rabbit or rabbit-anti goat secondary antibodies for 60 minutes, and stained
with Vectastain ABC kit (Vector Laboratories) according to the manufacturer’s instructions.
Each step was followed by washing the sections with PBS containing 0.3% Triton X100.
Sections incubated without primary antibody were used as negative controls.
Determination of IκB Overexpression by Immunofluorescence. For detection of IκB in PVN
tissue, slides were incubated overnight at 4ºC with a 1:100 dilution of goat polyclonal anti-IκB
(Santa Cruz) as previously described (Cardinale, Sriramula et al. 2010).
p65 Activity Assay for Assessment of NF-kB Binding Activity. The NFκB/p65 TransAM
Active ELISA kit (Active Motif) was used to measure the binding activity of free NFκB p65 in
nuclear extracts (Active Motif). The extraction and analysis were done using a sandwich ELISA

110

method and in accordance to the manufacturer’s instructions. Procedure yields 0.15-0.25mg of
nuclear extract from PVN tissue at 3-5mg/ml. NFκB/p65 Active ELISA detection levels for
nuclear extracts between 0.5-1μg/well at 450nm.
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Figure 5.1. PVN specific inhibition of NFκB. (A) Schematic showing cannulae
placement/microinjection stereotaxic location coordinates. (B) Representative
immunofluorescence image for IκB is localized in the PVN following AdIκB bilateral
microinjection into control rat. (C) NFκB p65 activity assay showing increased activity in the
PVN of the AngII-treated groups when compared to control groups. p65 activity is decreased
in AngII-treated rats following bilateral PVN NFκB decoy infusion or AdIκB microinjection.
n=5-6 rats per group, *p<0.05 vs respective AngII-treated rats, #p<0.05 vs respective controltreated rats.
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Statistical Analysis. All results are expressed as mean±SEM. For statistical analysis of the data,
student’s t test, one-way ANOVA or repeated measures ANOVA followed by Bonferroni’s
correction post hoc was performed (GraphPad Prism v5.0 for Windows, GraphPad Software, San
Diego California, USA) to determine differences among groups. A value of p<0.05 was
considered statistically significant.
RESULTS
NFκB Blockade in the PVN
Reduces p65 Subunit Binding
Activity. To determine the role of
NFκB inhibition in the central
regulation of blood pressure, we
either bilaterally infused NFκB
decoy oligodeoxynucleotide into
the PVN via a fixed cannula
(Figure 5.1A) or bilaterally
microinjected an Adenovirus
encoding serine mutated IκB to
overexpress IκB and inhibit
NFκB within the PVN. Figure
5.1B shows the localization of
IκB gene overexpression
specifically within the PVN

Figure 5.2. Localizaion of treatment sites within the
PVN. Bilateral cannulae placement (A; n=22) and
microinjection (B; n=24) sites as determined by postmortem analysis of the brain using crystal violet staining
prior to punching the PVN and immunohistochemical
slicing. Rats demonstrating unilateral treatments also
demonstrated an elevated MAP from the bilaterally
treated AngII+Scramble decoy, AngII+AdEmpty, AngII+
NFκB decoy and AngII+ AdIκB groups.

following bilateral PVN AdIκB
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microinjection, as indicated by enhanced fluorescence protein expression. Localization of
injection sites of examined rats are schematically represented in Figure 5.2. To determine the
efficacy of the two methods inhibiting NFκB activity, an NFκB p65 subunit activity assay was
conducted following 14-day treatment in the PVN. The p65 subunit activity was dramatically
increased in the PVN in the two AngII-treated groups versus their respective controls (Figure
5.1C). This increase in activity was attenuated in both AngII+NFκB decoy and Ang II+AdIκBtreated rats. This data indicates that NFκB is increased within the PVN during the AngII-induced
hypertensive response and that the use of NFκB decoy or AdIκB can potently, and site
specifically, inhibit the activity of NFκB.

165

Ang II/NFB inhibition

mmHg

150

#

135

#
# #
#
#

#

#

#

Ang II+Scramble decoy
Ang II+AdEmpty
Ang II + Unilateral
NFB decoy
Ang II + Unilateral
AdIB
Ang II + NFkB decoy
Ang II + AdIkB
Saline+NFkB decoy
Saline+AdkB
Control

# # #

* * * * * * *
* * * * *
* * *

120
105
90
0

5

10

15

Days

Figure 5.3. Effects of NFκB inhibition on AngII-induced increases in MAP. AngII
continuously increased MAP in centrally treated control rats. Bilateral NFκB decoy infusion
or AdIκB microinjection into the PVN decreased this AngII-induced increase in MAP.
Unilateral PVN NFκB blockade only partially decreased the AngII-induced MAP. n=78/group, *p<0.05 vs respective AngII-treated rats, #p<0.05 vs respective control-treated rats.
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Figure 5.4. Effects of NFκB inhibition on AngII-induced increases in PIC expression. (A)
mRNA expression of the PICs TNF, IL-1β, IL-6 and MCP-1 in the PVN of Ang II-infused
groups are increased versus control groups. Expression is decreased following bilateral PVN
NFκB decoy infusion or AdIκB microinjection. (B) Immunohistochemical staining for TNF is
increased in the PVN in AngII-infused rats (AngII alone) versus Controls (no treatment).
Staining was decreased in rats treated bilaterally into the PVN via NFκB decoy infusion or
AdIκB microinjection. Images shown represent results observed in preparations from 4 to 6
rats. n=6-8/group, *p<0.05 vs respective AngII-treated rats, #p<0.05 vs respective controltreated rats.
NFκB Blockade in the PVN Attenuates the AngII-Induced Blood Pressure Response. To
assess the effect of NFκB inhibition in the PVN on AngII-induced hypertensive response, mean
arterial pressure (MAP) was measured using a radio-telemetry system (Figure 5.3). Chronic 14day AngII infusion significantly increased the MAP in rats that received scramble decoy or
AdEmpty treatment versus their respective saline-infused controls (Saline+NFκB decoy and
Saline+AdIκB). In contrast, the MAP in AngII+NFκB decoy and AngII+AdIκB had a
significantly reduced MAP, though the MAP was not decreased to control levels. Rats receiving
either treatment unilaterally, though showing a reduced MAP versus the AngII control groups
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was not reduced as effectively as bilateral treatments. This data indicates that NFκB within the
PVN plays a contributing role to blood
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Figure 5.5. Effects of NFκB inhibition on
AngII-induced changes in RAS component
expression. (A) Mas/AT1R ratio and western
densitometry for AT1R (B) and the Mas
receptor (C). Bilateral PVN NFκB decoy
infusion or AdIκB microinjection decreased the
AngII-induced increase in AT1R and increased
the AngII-induced decrease in Mas receptor
protein expression. n=6-8 in each group,
*p<0.05 vs respective AngII-treated rats,
#
p<0.05 vs respective control-treated rats.

of AdIκB into the PVN attenuated these
changes in PIC gene expression (Figure
5.4A). Furthermore, immunohistochemistry
against TNF showed an increase in staining
in AngII-treated rats (AngII alone) versus
Controls (no treatment) (Figure 5.4B). This

protein expression was reduced via bilateral PVN NFκB decoy infusion or bilateral AdIκB
microinjection into the PVN, demonstrating that through NFκB inhibition within the PVN, PIC
levels are reduced within this hypothalamic region.
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Figure 5.6. Effects of NFκB inhibition on Ang II-induced changes in RAS component
expression. (A) mRNA expression of AT1R and ACE was increased, while ACE2 and the
MasR were decreased in the Ang II-treated rat groups when compared to controls. Bilateral
PVN NFκB decoy infusion or AdIκB microinjection reversed these changes. (B) Western
blots showed that AT1R is increased, while the MasR is decreased in Ang II-treated rats (Ang
II alone) when compared to Controls (no treatment). Bilateral PVN NFκB decoy infusion or
AdIκB microinjection reversed these changes. n=6-8/group, *p<0.05 vs respective Ang IItreated rats, #p<0.05 vs respective control-treated rats.
NFκB Blockade Effects RAS Component Expression in the PVN. To study the effect of
NFκB on RAS components, the expression levels of ACE and ACE2 by PCR, and AT1R and
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Mas receptor (MasR) by PCR and western blot, were analyzed. AngII infusion significantly
increased the mRNA expression of the AT1R and ACE in the PVN when compared with control
rat groups, and decreased the ACE2 and MasR expression versus their respective control groups
(Figure 5.6A). Bilateral NFκB decoy
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analysis. These results show that NFκB
plays a modulatory role in RAS
component expression in the PVN during
the AngII-induced hypertensive response.
NFκB Blockade Reduces ROS
Production in the PVN. To study the
effects of NFκB blockade on ROS
production in the PVN, ROS levels were

Figure 5.7. Effects of NFκB inhibition on Ang
II-induced changes in ROS levels. AngIIinfused rats (Ang II alone) had an increase in
total ROS, superoxide and peroxynitrite within
the PVN versus Control rats (no treatment).
Bilateral PVN NFκB decoy infusion or AdIκB
microinjection decreased these changes in ROS
within the PVN. EPR spectra (right) for total
ROS and superoxide. Graphical data when
compared to total protein/sample. n=5-6/group,
*p<0.05 vs respective Ang II-treated rats,
#
p<0.05 vs respective control-treated rats.

measured by EPR analysis (Figure 5.7).
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Total ROS, superoxide and peroxynitrite levels were significantly increased in the PVN of
AngII-treated rats (AngII alone) versus Controls (no treatment). These ROS levels were
decreased to normal levels following chronic bilateral NFκB decoy infusion or AdIκB
microinjection into the PVN, indicating the role that NFκB plays in increasing ROS during the
hypertensive response.
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Figure 5.8. Effects of NFκB inhibition on Ang II-induced increases in nNOS expression.
(A) mRNA expression of nNOS in the PVN of Ang II-infused rat groups is decreased versus
control rat groups. Expression is increased following bilateral PVN NFκB decoy infusion or
AdIκB microinjection. (B) Immunohistochemical staining for nNOS is increased in the PVN
in AngII-infused rats (Ang II alone) versus Controls (no treatment). Staining was increased in
rats treated bilaterally into the PVN via NFκB decoy infusion or AdIκB microinjection.
Images shown represent results observed in preparations from 4 to 6 rats. n=6-8/group,
*p<0.05 vs respective Ang II-treated rats, #p<0.05 vs respective control-treated rats.
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NFκB Blockade Increases nNOS Expression in the PVN. Neuronal NOS (nNOS) expression
is an indirect indicator of sympathoexcitation. In AngII-treated rat groups, nNOS mRNA was
significantly decreased when compared to the control rat groups (Figure 5.8A). Bilateral NFκB
decoy infusion or AdIκB microinjection into the PVN reversed and elevated these AngII-induced
changes even beyond that of the normotesive controls. These results were further confirmed with
immunohistochemistry against nNOS (Figure 5.8B), where AngII-infused rats (AngII alone) had
decreased nNOS presence versus Controls (no treatment). Expression levels were elevated in
AngII+NFκB decoy and AngII+AdIκB groups, indicating that through reduction of NFκB,
nNOS, and potentially sympathoexcitation, were beneficially decreased in the AngII-induced
hypertensive state.
DISCUSSION
In the present study, we investigated the effects of site specific bilateral hypothalamic
PVN blockade of NFκB on the AngII-induced hypertensive response. The salient findings of this
study are as follows: 1) Peripheral AngII infusion increases MAP and bilateral PVN NFκB
blockade attenuates this elevated MAP; 2) Peripheral AngII infusion, within the PVN, increases
PICs, ROS and pro-hypertensive (ACE and AT1R) RAS components, while decreasing the antihypertensive (ACE2 and Mas) RAS components; 3) bilateral PVN specific NFκB inhibition not
only decreases PVN PICs, but also modulates RAS component expression, such as decreasing
ACE and AT1R expression and increasing ACE2 and MasR expression; 4) PVN blockade of
NFκB leads to an increase in nNOS expression and a decrease in O2•− and peroxynitrite (OONO•)
levels. These results indicate that the NFκB-modulated inflammatory response acts as a doubleedged sword that not only increases the deleterious pro-hypertensive arm of the RAS, but also
decreases the protective anti-hypertensive arm of the RAS, possibly through a ROS mechanism.
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The NFκB response is triggered by phosphorylation of IκB, which then becomes
ubiquinated, is degraded, and frees NFκB, allowing its nuclear translocation to act on κB binding
sites and commence transcription (Barnes and Karin 1997). In this study, two approaches were
utilized to block NFκB within the PVN. AdIκB binds to NFκB similar to endogenous IκB, but
serine mutations at the S32A/S36A positions prevent the IκB phosphorylation and ensuing NFκB
release, thwarting its capability to translocate into the nucleus and transcribe target genes
(Gilmore 2006). Decoy oligodeoxynucleotides act by targeting and adhering to the cis-element
binding sites of free NFκB, thereby preventing its binding to κB gene binding sites and also
blocking subsequent gene transcription (Morishita, Sugimoto et al. 1997; Morishita, Higaki et al.
1998). These two methods block NFκB transcription capabilities at two separate activation
pathway locations: prior to entering the nucleus (AdIκB), and after being freed from IκB (NFκB
decoy). This redundancy of blockade effectively demonstrates the role of PVN NFκB in AngIIinduced hypertension, potentially signifying that there are no tangential pathways activated in the
interim between NFκB release from IκB and NFκB’s nuclear translocation. Previous findings
from our lab investigating the role of the PVN in AngII-induced hypertension demonstrated that
NFκB within the PVN was differentially regulated along with PIC and oxidative stress genes and
proteins (Kang, Ma et al. 2009). The study presented the involvement of brain NFκB in
regulating the hypertensive response, a previously novel proposal. However, in the study,
intracerebroventricular (ICV) infusion of PDTC, a known antioxidant (Moellering, McAndrew et
al. 1999), was used to investigate NFκB in the PVN in hypertension, indicating that NFκB could
have been reduced through an antioxidant mechanism rather than direct NFκB blockade. Also,
due to ICV administration, it could not rule out the possible involvement of other affected
cardio-regulatory regions for the observed reduction in the hypertensive response. Therefore, the
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exact role and proposed involvement/mechanism of NFκB within the PVN was still uncertain.
The current study looks specifically at NFκB blockade within the PVN in the AngII-induced
hypertensive response, delineates the involvement of PVN NFκB in regulating ROS and PIC
expression, and potentially shows that NFκB serves as a tipping point trigger between the prohypertensive and protective anti-hypertensive arms of the RAS within the PVN.
Extensive evidence has implicated the RAS in the brain in hypertension (GorbeaOppliger and Fink 1995; Davisson 2003; Veerasingham and Raizada 2003). Within the PVN, an
important central cardio-regulatory region, AngII is increased in multiple hypertensive animal
models and PVN blockade of the AT1R partially inhibits the effects of AngII-induced
hypertension (Gorbea-Oppliger and Fink 1995; de Wardener 2001; Veerasingham and Raizada
2003; Silva, Santos et al. 2005; Kang, Ma et al. 2009). In the current study, following NFκB
blockade within the PVN, ACE and the AT1R were decreased, thereby limiting the effect that
AngII could have on perpetuating AngII-induced hypertension. Moreover, and perhaps more
importantly, NFκB inhibition also increased ACE2 and MasR expression, as well as improved
the Mas/AT1R ratio, indicating enhancement of the protective anti-hypertensive axis of the RAS.
ACE2 is the counterpoint to ACE, in that instead of converting AngI to AngII, AngI and AngII
are converted to Ang(1-7) (Xu, Sriramula et al.), which acts on the MasR to elicit actions
opposing those of AngII, including vasorelaxation and decreased sympathetic activity (DiezFreire, Vazquez et al. 2006; Ferrario 2006; Yamazato, Yamazato et al. 2007). Our results agree
with other findings detailing the anti-hypertensive actions of ACE2 and the MasR (Diez-Freire,
Vazquez et al. 2006; Yamazato, Yamazato et al. 2007), including their interplay with, and
decreased activity following, AT1R activation within the brain (Ferrario 2006; Feng, Yue et al.
2008; Xia, Feng et al. 2009; Feng, Xia et al. 2010). Combined, these results suggest NFκB as an
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important tipping point between the protective (ACE2/Ang(1-7)/Mas) and non-protective
(ACE/AngII/AT1R) arms of the RAS, and that NFκB blockade promotes the more beneficial
actions of ACE2 and the MasR.
The association between the RAS and elevated PICs in hypertension has often been
explored, with many confirming more than a casual relationship between these two systems in
the disease state (Chae, Lee et al. 2001; Sun, Li et al. 2004; Sriramula, Haque et al. 2008; Lu,
Chen et al. 2009). NFκB is a key regulator of the PIC expression and inflammatory response
speculated to have a role in the inflammatory component of hypertension (Cowling, Gurantz et
al. 2002; Kang, Ma et al. 2009; Cardinale, Sriramula et al. 2010). Here, we show that bilateral
NFκB inhibition in the PVN reduces PIC expression, establishing not only the definitive
involvement of NFκB within the PVN in regulating the AngII-induced hypertensive response,
but also that PICs may play a role in RAS modulation. Recently, ROS, especially O2•−, have been
shown as important signaling factors within the brain for enhancement of sympathetic outflow
and increased hypertensive response through both AngII and PIC mechanisms (van den Berg,
Haenen et al. 2001; Zhang, Wei et al. 2003; Zimmerman, Lazartigues et al. 2004; Guggilam,
Haque et al. 2007). In this study, bilateral NFκB blockade reduced the ROS response, including
that of O2•−, thus potentially inhibiting one of the mechanistic pathways by which
sympathoexcitation is modulated. These results are further confirmed by previous experiments in
our lab showing a reduction of renal sympathetic nerve activity in AngII-treated rats following
ICV administration of the ROS scavenger, Tempol (Kang, Ma et al. 2009). Here we show that
PVN specific NFκB blockade reduced the PIC and ROS reactions typically associated with
AngII-induced hypertension, highlighting the central position that PVN NFκB plays in regulating
the neurogenic component of the hypertensive response.
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Symapthoexcitation is a major component of hypertension, and increased levels of AngII
in the CNS can enhance sympathetic outflow through ROS and AT1R activation and a
subsequent down-regulation of nNOS (Zanzinger, Czachurski et al. 1995; Liu, Murakami et al.
1998; Campese, Shaohua et al. 2005; Gao, Wang et al. 2005; Guggilam, Cardinale et al. 2011),
and the PVN plays a role in modulating sympathetic outflow (Allen 2002). NO, a well known
sympatho-inhibitory neurotransmitter, when blocked, results in elevated MAP and
sympathoexcitation (Campese, Ye et al. 2002; Campese, Shaohua et al. 2005). The expression
and presence of nNOS, an indirect indicator of downstream sympathetic activity, is inversely
proportional to the level of sympathetic outflow (Wang, Liu et al. 2005; Li, Wang et al. 2006;
Guggilam, Patel et al. 2008). Furthermore, increased superoxide can interact with the nNOSproduced NO, forming OONO• and further affecting the decrease in NO bioavailability, also
resulting in enhanced sympathoexcitation (Zanzinger 2002; Yu, Zhang et al. 2010). Recently,
Ang(1-7) and MasR activation have been shown to increase nNOS activity and NO release
(Sampaio, Souza dos Santos et al. 2007). The current study shows that following AngII
treatment, nNOS is decreased within the PVN, potentially indicating an increased sympathetic
response. Also in the present study, OONO• was increased in the AngII-treated rats, which,
following bilateral NFκB inhibitor administration, was decreased. The OONO• decrease
paralleled that of O2•− and was concurrent with the nNOS increase, indicating that NFκB plays
potentially a deciding role in increasing NO availability and regulating sympathetic outflow.
Therefore, bilateral NFκB inhibition increased nNOS and reduced O2•− and OONO•, potentially
through protective RAS component balance, thus increasing nNOS and the capacity for NO
availability and potentially decreasing subsequent sympathetic outflow.
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In conclusion, this study shows that following the activation of the pro-hypertensive arm
of the RAS, PICs are increased, both of which can act to increase the activity of NFκB, leading
to the transcription of additional modulators of the hypertensive state in a positive feed-forward
manner. NFκB acts further to increase, along with AngII, the presence of ROS, such as O2•−,
which subsequently affects the present NO levels, thereby increasing sympathoexcitation.
Blockade of NFκB at two separate locations in its activation pathway prevents these changes,
restoring balance and promoting the anti-hypertensive arm of the RAS, including ACE2 and the
MasR, as well as reducing PIC and ROS expression and elevating nNOS, all of which
contributes to a reduction in MAP and an improvement in the AngII-induced hypertensive state.
However, this signaling mechanism must be further studied to delineate the manner by which
NFκB and O2•− interact within the PVN in AngII-induced hypertension. We propose that AngII
activation of NFκB increases PICs and O2•−, tipping the balance of the RAS in favor of the prohypertensive arm and decreasing the anti-hypertensive arm, resulting in a further increase in PIC
and ROS expression, in a vicious positive feed-forward mechanism (Figure 5.9). Limitations for
this study include the use of the AngII-induced hypertensive model, since this does not represent
all modes of hypertension. Furthermore, we only explored the PVN region in this hypertensive
model. There are multiple cardio-relevant regions of the brain that can play a role in modulating
the hypertensive response; however, we feel that the PVN is of importance due to its integrative
functions. Moreover, as the literature suggests, Adenoviruses are well known for their lack of
cell specificity and can be expressed by neurons and glia as well as participate in retrograde
transport (Sinnayah, Lindley et al. 2002). For this reason, we employed NFκB decoy
oligodeoxynucleotides to further verify our results. Finally, to show the minimal effects of the
potential perfusion of bilateral PVN NFκB decoy infusion leakage into the third ventricle and its
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subsequent effect on other regions of the brain, ICV infusion of the same dose at the same
infusion rate could have been performed, but we feel, based on similar experiments, that though
third ventricle leakage may have occurred, its effects would be negligible. In the current clinical
environment where novel hypertensive therapeutic measures are being sought, this study
provides a conceptual basis for including NFκB inhibitors that can specifically act within the
brain as a possible future pharmacological approach for the treatment of hypertension.

PVN

AngII

O2•−

AdIκB or
NFκB Decoy
ONOO−

NFκB

NO +

O2•−

PIC

AT1R
ACE
MasR
ACE2

Sympathoexcitation
and Hypertensive Response
Figure 5.9. Schematic showing the proposed signaling mechanism in the PVN. Ang II
leads to an exasperated hypertensive response via NFκB and modulation of the balance
between the pro- and anti-hypertensive arms of the renin-angiotensin system (solid
lines/arrows) and how NFκB inhibition attenuates this response (green lines/arrows). Ang II
activates NFκB via an AT1R/superoxide pathway. NFκB increases transcription of PICs and
ROS production genes, as well as the pro-hypertensive RAS components, while decreasing the
anti-hypertensive RAS components. The increased PICs and ROS positively feeds back upon
NFκB (while also signaling for increased sympathetic outflow). These signals combine to
propagate the hypertensive state.
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PERSPECTIVES
Increasing evidence indicates that central nervous system mechanisms play an important
role in the pathogenesis of cardiovascular disease. In this study, we demonstrate that
inflammatory molecules, specifically the transcription factor NFκB, within the PVN, can
modulate the hypertensive response. Additionally, we demonstrate that inflammation is a
double-edged weapon that not only up-regulates the pro-hypertensive axis of the RAS, but also
down-regulates the protective anti-hypertensive axis of the RAS. Thus, inflammation-mediated
modulation of the RAS system within the brain might be an important critical contributor to
neurogenic hypertension. Since inflammation and RAS are potent inducers of oxidative stress
and NFκB has been shown to respond to and induce oxidative stress, it would be advantageous to
target NFκB to better treat neurogenic hypertension. While the current methods used within this
study are impractical for current clinical administration, one can explore the use of NFκB small
molecule inhibitors that might cross the BBB, thereby targeting the brain’s source of
inflammation and oxidative stress for controlling and treating this debilitating condition.
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CHAPTER 6
CONCLUDING REMARKS
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OVERALL SUMMARY OF FINDINGS
Hypertension is one of the world’s great public health problems, affects more than 74
million American adults, and is the leading cause of death worldwide (2002; Lloyd-Jones,
Adams et al. 2010). Hypertension is not only a serious condition with its own high morbidity and
mortality rates, it is also a major risk factor for multiple cardiovascular diseases (CVDs),
including myocardial infarction, stroke, heart failure, atrial fibrillation and peripheral arterial
disease. Moreover, with the rise in additional causes for increased blood pressure, including
obesity, excessive salt intake, poor lifestyle choices and a growing population of aging
individuals, the incidence of hypertension is rising (Lloyd-Jones, Adams et al. 2010). While the
condition is easily detectable, it still remains poorly controlled in more than half of identified
hypertensive patients. Current therapeutics for primary hypertension are multiple and varied,
targeting and exploiting the many endogenous controlling mechanisms of normal pressure
response as well as pathophysiological contributors towards hypertension (Izzo, Sica et al. 2008).
However, many of these therapies fail to have a beneficial effect, prompting the need for novel
therapeutic approaches and a greater understanding of the mechanistic pathways involved in the
pathogenesis and maintenance of hypertension.
Recent evidence suggests that hypertension is a chronic low-grade inflammatory
condition where pro-inflammatory cytokines (PICs), such as tumor necrosis factor-alpha (TNF),
interleukin (IL)-1β and IL-6, have emerged as major contributing factors in the pathogenesis of
hypertension and other CVDs (Mann 2002; Ruiz-Ortega, Ruperez et al. 2002; Ferrario and
Strawn 2006; Sriramula, Haque et al. 2008; Kang, Ma et al. 2009; Cardinale, Sriramula et al.
2010). The renin-angiotensin system (RAS), especially the effector peptide angiotensin II (Ang
II), not only modulates the hypertensive response, but also induces the inflammatory response
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associated with hypertension (Kalra, Sivasubramanian et al. 2002). Moreover, this inflammatory
response is capable of regulating local and systemic RAS components, including increasing the
pro-hypertensive axis (Ang II, angiotensin converting enzyme (ACE) and Ang II type-1 receptor
(AT1R)) while silencing those of the anti-hypertensive axis (ACE2, AT2R, Ang (1-7) and the
Mas receptor). The Ang II-mediated inflammatory response appears to occur through several
mechanisms, including activation of monocytes and macrophages, as well as the production of
adhesion molecules, chemokines, PICs and reactive oxygen species (ROS) (Arenas, Xu et al.
2004; Shi, Diez-Freire et al. 2010). While still not fully known, the interaction of these various
hypertensive regulatory pathways are becoming increasingly important to understand, especially
in regards to their contribution towards the pathogenesis of hypertension. Therefore, elucidating
the mechanism by which these signaling pathways interact is critical for the development of
novel therapeutics in the fight to control the debilitating effects of hypertension.
Chapter 2 acknowledges evidence that the RAS and Ang II can increase the production of
PICs and contribute to the hypertensive state, and that blocking the PIC TNF can prevent some
of the deleterious changes associated with hypertension and the ACE/Ang II/AT1R RAS axis
(Funakoshi, Ichiki et al. 1999; Kalra, Sivasubramanian et al. 2002; Muller, Shagdarsuren et al.
2002; Ruiz-Ortega, Ruperez et al. 2002; Elmarakby, Quigley et al. 2006). The suggested
mechanism potentially involved a positive feed-forward system whereby Ang II increases TNF
and ROS, which in turn further increases injurious ACE/Ang II/AT1R RAS axis components,
and decreases protective ACE2/Ang (1-7)/Mas RAS components. Therefore, we aimed to
determine if administration of TNF alone could regulate components of the RAS, and if so, was
this mechanism achieved through modulation of ROS. TNF infusion for five days increased the
components of the deleterious axis of the RAS, including angiotensinogen, ACE, Ang II and the
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AT1R. TNF infusion also increased gp91phox (the NADPH oxidase catalytic subunit), total ROS
and superoxide, and decreased the protective RAS components ACE2 and the Mas receptor.
These changes were reversed following administration of the superoxide dismutase (SOD)
mimetic, Tempol, or the TNF receptor mimetic, etanercept, indicating that the TNF-induced
TNF-driven pathway required ROS, especially superoxide, for dysregulation of the individual
RAS arms and propagation of the hypertensive state. In conjunction with the understanding that
Ang II increases TNF and that use of PIC and ROS inhibitors can reduce the hypertensive
response, we demonstrate here that the ROS appears to evolve through a TNF-activated
mechanism, therefore highlighting the Ang II/TNF/ROS pathway. This pathway in turn reduces
the protective RAS axis (ACE2/Ang (1-7)/Mas) while up-regulating the more injurious aspects
of the pro-hypertensive RAS arm (ACE/Ang II/AT1R). This study underscores the role that TNF
plays in the ROS-induced dysregulation of the RAS and the ROS-driven mechanism behind
TNF-induced cardiac dysfunction, further spotlighting the role that PICs such as TNF may play
in the differential RAS regulation in the pathogenesis of the hypertension.
Chapter 3 discusses the interaction between the RAS, PICs and ROS demonstrated by
work in our laboratory and others (Brasier, Li et al. 1996; Sasamura, Nakazato et al. 1997;
Arenas, Xu et al. 2004; Sriramula, Haque et al. 2008). Here we showed that untreated
spontaneously hypertensive (SHR) rats have increased AT1R expression, an important
component of the pro-hypertensive portion of the RAS. Histone Deacetylase inhibition (HDACi)
through valproic acid (VPA) treatment attenuated this increase and the increased production of
PICs. Reports previously indicated that Ang II is controlled by, and controls, HDAC-induced
changes in gene and protein response (Kee, Sohn et al. 2006; Lu and Yang 2009). Here we show
a possible new mechanism involving the regulation of Ang II responses as directed through the

134

AT1R. HDACi reduces AT1R gene expression and receptor density, thereby ameliorating the
actions of Ang II. This alteration in AT1R expression could be either through direct HDACi
effects on the receptor’s production and function, or through the effects of HDACi on
inflammatory gene response during hypertension. Thus, results of this study showed that longterm HDACi through VPA attenuated mean arterial pressure (MAP) and cardiac hypertrophy,
possibly through modulation of atrial natriuretic peptide (ANP), Collagen IV and AT1R. HDAC
inhibition also attenuated the increased inflammatory response, including TNF and nuclear
factor-kappaB (NFκB), as well as the increase in ROS and gp91phox. These findings suggest
that HDACi with VPA reduced inflammation, ROS, and AT1R, thereby attenuating hypertension
and its secondary consequences in SHR rats.
In Chapter 4, we demonstrated that chronic Ang II infusion resulted in cardiac
hypertrophy and hypertension, increased PIC and gp91phox, and decreased expression of
neuronal Nitric Oxide Synthase (nNOS) within the hypothalamic paraventricular nucleus (PVN).
Perhaps more importantly, Ang II-infused rats had an increased expression of the injurious prohypertensive RAS components ACE and AT1R, and a decreased expression of the protective
anti-hypertensive RAS components ACE2, AT2R and the Mas receptor. Central blockade of TNF
with etanercept resulted in attenuation of hypertension, cardiac hypertrophy and PIC expression,
decreased oxidative stress, as well as a restored balance between the protective and deleterious
RAS arms within the hypothalamic PVN. The beneficial effects of central TNF blockade in Ang
II-induced hypertensive responses appear to be mediated by the returned balance of the central
RAS, especially within the PVN. Our findings provide further evidence for the involvement of
the RAS within the PVN and its interaction and mediation through TNF in the neurogenic
component of hypertension.
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Finally, in Chapter 5, we demonstrated that following the activation of the prohypertensive arm of the RAS, PICs are increased, both of which can act to increase the activity
of NFκB within the PVN. This in turn leads to the transcription of additional modulators of the
hypertensive state in a positive feed-forward manner that contributes to the hypertensive state.
Furthermore, NFκB acted to increase, along with AngII, the presence of ROS, such as
superoxide, which subsequently decreased the presence of Nitric Oxide (NO), thereby increasing
sympathoexcitation. Blockade of NFκB within the PVN at two separate locations in its activation
pathway, prior to entering the nucleus (via PVN transfection with an Adenoviral vector
containing Inhibitory-kappaB), and after nuclear translocation (via PVN infusion of NFκB decoy
oligodeoxynucleotide), prevented these changes. These treatments promoted the antihypertensive arm of the RAS, including ACE2 and the Mas receptor, as well as reducing PIC and
ROS expression, and elevating nNOS, all of which contributes to a reduction in MAP and an
improvement in the AngII-induced hypertensive state. Therefore, we proposed that AngII
activation of NFκB within the PVN increases PICs and superoxide, tipping the balance of the
RAS in favor of the pro-hypertensive arm and decreasing the anti-hypertensive arm, resulting in
an even further increase in PIC and ROS expression, resulting in a vicious and positive feedforward mechanism.
SIGNIFICANCE OF RESEARCH AND FUTURE DIRECTIONS
Current treatment regimens for hypertension are only partially effective in controlling the
disease state. These therapeutics act on the endogenous mechanisms that control pressure
response in normal and pathological conditions. Briefly, these therapies can include lifestyle
modifications and/or a multitude of pharmacological therapeutics. Lifestyle modifications can
include weight reduction, sodium reduction, diet modification, increased physical activity and
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moderation of alcohol and tobacco consumption, amongst others. Common pharmacological
interventions can include any number of drugs alone or in combination, including, but not
limited to, diuretics, β-blockers, α1-blockers, Ca2+ channel blockers, ACE inhibitors and
angiotensin receptor blockers (ARBs) (Izzo, Sica et al. 2008). However, while many current
therapeutics have clearly reduced the morbidity and mortality of some hypertensive patients,
they still fail to have a beneficial effect on over 50% of treated individuals, prompting the need
for novel therapeutic approaches and a greater understanding of the mechanistic pathways
involved in the pathogenesis and maintenance of hypertension.
The complexity and somewhat unclear signaling mechanisms involved in hypertension
are of intense investigational interest. Recent evidence shows that hypertension is a chronic lowgrade inflammatory condition (Ferrario and Strawn 2006; Sriramula, Haque et al. 2008; Kang,
Ma et al. 2009; Cardinale, Sriramula et al. 2010) where PICs, such as TNF, have emerged as
major contributing factors in the pathogenesis of hypertension (Mann 2002; Ruiz-Ortega,
Ruperez et al. 2002; Sriramula, Haque et al. 2008; Kang, Ma et al. 2009). Despite the
overwhelming evidence linking TNF to CVDs, large clinical trials targeted against this PIC have
been largely unsuccessful (RENAISSANCE, RECOVER and ATTACH) (Anker and Coats
2002; Mann, McMurray et al. 2004); it is speculated that the lack of success of these trials lies
not in the use of anti-cytokine agents, but the use of system wide TNF inhibition and the
consequences resultant from this type of therapy (Mann, McMurray et al. 2004). Therefore, the
need for improved knowledge of the contributing pathways to hypertension, and the requirement
for continued therapeutic developments remain of the utmost importance. The studies conducted
herein provide significant advancements in delineating mechanistic pathways and potential
therapeutic targets for the treatment of hypertension.
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The studies described here underscore the role that inflammation plays in hypertension
and the means by which it is regulated, providing a strong foundation for the future development
of novel therapeutic options. It shows that TNF plays a major part in the ROS-induced
dysregulation of the RAS and the ROS-driven mechanism behind TNF-induced cardiac
dysfunction. These studies also show how central blockade of TNF with etanercept can attenuate
hypertension, cardiac hypertrophy and PIC expression, decrease oxidative stress, and restore the
balance between the protective and deleterious RAS arms, within the hypothalamic PVN,
pointing to a role for TNF in the neurogenic component of hypertension as well. Furthermore,
we proposed that AngII activation of NFκB within the PVN increases PICs and superoxide,
tipping the balance of the RAS in favor of the pro-hypertensive arm and decreasing the antihypertensive arm, resulting in sustained hypertension. This study showed that specifically
targeting NFκB within the PVN can attenuate the hypertensive state, providing a conceptual
basis for including NFκB inhibitors that can specifically act within the brain as a possible future
pharmacological approach for the treatment of hypertension. Finally, we demonstrated how the
use of VPA, an anti-seizure and bipolar drug currently used in clinical settings, administered
long-term without any adverse effects towards the treated animals, was successful in the
treatment of hypertension and its consequences, including cardiac hypertrophy, systemic
inflammation and end organ damage due to ROS. This study outlines the importance of the
continuous drug administration necessary to treat hypertension and also provides sufficient
evidence for the use of HDACi to reduce not only blood pressure, but cardiac hypertrophy and
the inflammatory state associated with hypertension. Whereas ACEi and ARBs only target a
portion of the systemically activated RAS, combined, these studies identify the involvement of
several inflammatory mediators (TNF, NFκB and HDAC), through ROS, in activating and
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dysregulating the local RAS within the heart and brain and contributing to the pathogenesis and
sustainment of hypertension.
Although we believe that these studies identify novel pathways through which TNF,
NFκB, ROS and the RAS interact in the heart and brain in hypertension, further studies are
required to understand the exact mechanistic pathways involved, as well as identify additional
possible therapeutic targets whose inhibition/activation would not lead to adverse responses (as
observed in several clinical trials against TNF). Further identification of additional mediators of
TNF and NFκB, determining the role of additional cardio-regulatory centers in the brain in the
hypertensive response, and elucidating how peripheral modulators signal to the brain, would all
greatly improve this knowledge base. Moreover, a closer look at the protective axis of the RAS
provides an appealing option for the future of therapeutics. Based on these studies, a clear link
between inflammatory mediators and the dysregulation of the RAS is clear, but more work must
be done to develop safe and effective means by which to positively influence this mechanism.
Other issues also present both challenges and avenues of exploration for future hypertensive
studies. For instance, specific Sirtuins and hypoxia inducible factors (HIF) are known to interact
with NFκB and differentially regulate its actions, but how and in what pathological states this
occurs is unknown (Biala, Tauriainen et al. ; Miyazaki, Ichiki et al. 2008). Also, thus far, our labs
interest has been with the role of inflammation in the PVN, but attention must be made for the
rostral ventrolateral medulla (RVLM) and supraoptic nucleus (SON), amongst others, to
determine the signaling patterns between these regions and to the periphery and determine how
this signaling can be subjected to controlling in hypertension. Finally, speculations of the manner
by which peripheral signals interact with the brain are prevalent, but identifying this with more
certainty can ultimately lead to the development of better, more efficient therapeutics. All
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together, the data presented here, along with the contributions of current and future studies, will
go a long way in aiding in the identification of efficacious treatments in the constant pursuit to
alleviate patients suffering from the debilitating effects of hypertension.
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